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“The moral of the story . . . one should not try to second-guess microbes!  
If resistance is biochemically possible, it will occur.” 
 
Julian Davies, 2010 
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General introduction & outline of the thesis 
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Antibiotics, resistance and the resistome 
Since their discovery in 1928 by Alexander Fleming and their introduction for 
the treatment of infections in humans in 1941, antibiotics have truly 
revolutionized the field of infectious diseases. Since then, both minor and life 
threatening infections can be cured by these compounds, which either inhibit the 
growth of, or kill bacteria. Moreover, antibiotics are critical to the success of 
advanced surgical procedures, such as organ and prosthetic transplants, making 
them an invaluable asset to mankind. 
Within 70 years after introduction of antibiotics, the emergence of 
antimicrobial resistance has become a major threat to the effectiveness of these 
antimicrobial agents. Bacterial resistance to antibiotics is a naturally occurring 
phenomenon [1, 2], which has existed far longer than humans have [3]. The 
human use of antibiotics has, however, greatly increased the occurrence and 
spread of antimicrobial resistance among bacteria and resistance is increasingly 
encountered in the clinic [4]. Consequently, infections with such resistant bacteria 
require treatment with newer, often more broad spectrum, antibiotics. With a 
lack of novel antibiotics in the pipeline, we are now rapidly reaching the point 
where an increasing number of infections are extremely difficult to treat or may 
even become completely untreatable due to multidrug or pandrug resistance [5, 
6]. For this reason, a thorough understanding of the spread of antibiotic 
resistance is crucial to be able to limit its further dissemination and preserve 
existing antibiotics. 
Besides antibiotic resistance encountered in clinical pathogens, the collection 
of all antibiotic resistance genes (ARGs) in microbial ecosystems, known as the 
resistome, is also relevant. All microbes in such an ecosystem, including 
pathogenic, commensal and environmental bacteria, form a reservoir [7] from 
which antibiotic resistance can be acquired via a process called horizontal gene 
transfer (HGT) [8]. For this reason, antibiotic selection pressure on all microbes 
encountered in e.g. the human gut, but also those in animals, or even the 
environment may affect the emergence of resistance in other (potentially 
pathogenic) bacteria. This creates a complex interplay between antibiotic use and 
resistance throughout the global microbial community.  
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Studying the resistome: metagenomic techniques 
When studying the resistome of a microbial community, traditional culturing 
techniques would come with large drawbacks, as many bacterial species are not 
cultivable [9]. Molecular techniques in which total DNA (the metagenome) is 
extracted directly from a sample, provide a more complete representation of 
(antibiotic resistance) genes present in such a community. The resistome can be 
studied using various molecular techniques, including sequence-based, functional 
or targeted metagenomics. Each of these techniques have their own strengths 
and weaknesses (Figure 1), making each of them valuable for different purposes. 
With sequence-based techniques, the sequence of every kind of DNA (human, 
microbial etc.) present in a sample can be determined, which provides a wealth of 
information. This information can be used to study not only the taxonomic 
composition but also the functional capacity of a microbial community, including 
the resistome. However, analysis of such data is largely dependent on prior 
knowledge, since it relies on comparisons with annotated genes which have been 
deposited in existing reference databases [10]. 
Through functional metagenomics, DNA fragments from any metagenome are 
inserted into a vector (e.g., a plasmid), after which its functionality is investigated 
by expression in a heterologous host. Subsequently, the resulting transformants 
can be screened for the expression of resistance genes by growing them on 
antibiotic containing media. Such an approach is very useful for identifying 
previously uncharacterized genes and is thus independent of prior knowledge. 
Moreover, this technique can confirm whether a gene is functional, which adds to 
its reliability. This may also be a downside however, as functional DNA which 
cannot be expressed by the heterologous host is not detected. Also, this 
technique is quite labour intensive, making it less suitable for larger study 
populations [10, 11]. 
Throughout this thesis, targeted metagenomics has been the method of 
choice. In this approach, specific targets (in this case ARGs) can be amplified and 
detected [10]. As with sequence-based metagenomics, prior knowledge is 
required to be able to select for targets. The major strength of this technique is 
that it has a very high sensitivity compared to the previous two methods. 
Additionally, this method is less laborious, allowing for a high throughput and thus 
enabling its application in large epidemiological studies.  
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Figure 1. Comparison of  characteristics of three metagenomic techniques. 
Adapted from Sommer et al. [12] with permission. The different metagenomic 
techniques score variably with regards to: sensitivity (top corner), the degree 
which less abundant DNA sequences in a metagenome are included; 
independence of prior knowledge (right corner), how much it relies on previously 
determined DNA sequences; and reliability (left corner), how well its findings may 
be interpreted as functional resistance.  
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Aim and outline of the thesis 
Because of the interplay within microbial ecosystems, where resistance in one 
bacterium may disseminate to others, all resistance elements present in those 
ecosystems are potentially relevant to human health. Therefore, studying the 
resistome in addition to resistance in clinical isolates may provide a more 
comprehensive  understanding of the dissemination of antibiotic resistance. 
Because of its high density of microorganisms, the gut microbiota is perhaps one 
of the most accessible reservoirs of antibiotic resistance (9). The gastrointestinal 
tract is constantly exposed to numerous bacteria from the environment, e.g., 
food, water, soil, other humans, or animals. These incoming bacteria often 
harbour antimicrobial drug resistance genes (10), which can be transferred to the 
indigenous microbial communities (including opportunistic pathogens) through 
HGT [10, 13, 14]. The aim of this thesis was to contribute to our understanding of 
the microbial resistome in relation to the human gut microbiota. 
 
In chapter 2, the literature on the dissemination of antimicrobial resistance in 
microbial ecosystems is reviewed by discussing the concept of the resistome in 
detail, providing examples of HGT of clinically relevant ARGs and describing the 
contributions of the various HGT mechanisms to the spread of antibiotic 
resistance. 
While it is known that antibiotic resistant bacteria are present in the 
environment as well as in and on our body, there is very limited data on when and 
how such bacteria colonize our body. Are we born with resistant bacteria, or does 
gradual exposure in life slowly lead to their acquisition? In chapter 3, we explored 
the early development of the human gut resistome and potential deterministic 
factors, by investigating the longitudinal development of several antibiotic 
resistance genes (ARGs) of the infant gut resistome during the first months after 
birth. 
The dissemination of antibiotic resistance is affected and accelerated by 
various human activities. In an era of increasing globalization, the acquisition and 
dissemination of antibiotic resistant bacteria through international travel is a 
major concern. While exposure to antibiotic resistant bacteria during a travel is a 
risk for developing infections with such resistant bacteria, the trafficking of 
resistome elements could also lead to their introduction and further 
dissemination in other environments. In chapter 4A, we studied how the gut 
Chapter 1 
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resistome of travellers is affected by international travel. Next, in chapter 4B, we 
investigated whether several of the observations made concerning ARGs in the 
gut microbiome could be attributed to travel, or if they were also observable in a 
non-travelling study group.   
Continuing on international travel and acquisition of antibiotic resistance 
genes, there is currently no data available on the actual dynamics of the resistome 
during travel itself. It is for example not known how fast ARGs are acquired. In 
chapter 5 we therefore investigated the dynamics of the travellers’ resistome by 
monitoring several ARGs in the microbiomes of travellers during the course of 
their travels. 
The prevalence of extended spectrum beta-lactamase (ESBL) producing 
bacteria has increased greatly over the last decade. Such bacteria are 
unsusceptible to commonly used beta-lactamases, and are often resistant to 
many other antibiotics as well, leaving limited treatment options, such as the 
carbapenem antibiotics available. However, resistance to carbapenems is also 
increasing at an alarming rate, and has even become endemic in some regions in 
recent years. Consequently, infections with carbapenem resistant bacteria are 
often treatable only with last resort antibiotics such colistin. In November 2015 
however, the first plasmid mediated colistin resistance gene (mcr-1) was 
identified, heralding a major breach in our last line of defence. In chapter 6, we 
therefore investigated the presence of the mcr-1 gene in the gut resistome of 
Dutch international travellers, assessing its prevalence and risk of dissemination. 
Finally, in chapter 7, the results and findings of our studies are summarized 
and discussed. Furthermore we evaluate on the current standings of the antibiotic 
resistance problem, how investigating the resistome has contributed to our 
understanding of it, and discuss future perspectives.  
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Abstract 
The emergence and spread of antibiotic resistance among pathogenic bacteria 
has been a rising problem for public health in recent decades. It is becoming 
increasingly recognized that not only antibiotic resistance genes (ARGs) 
encountered in clinical pathogens are of relevance, but rather, all pathogenic, 
commensal as well as environmental bacteria – and also mobile genetic elements 
and bacteriophages – form a reservoir of ARGs (the resistome) from which 
pathogenic bacteria can acquire resistance via horizontal gene transfer (HGT). 
HGT has caused antibiotic resistance to spread from commensal and 
environmental species to pathogenic ones, as has been shown for some clinically 
important ARGs. Of the three canonical mechanisms of HGT, conjugation is 
thought to have the greatest influence on the dissemination of ARGs. While 
transformation and transduction are deemed less important, recent discoveries 
suggest their role may be larger than previously thought. Understanding the 
extent of the resistome and how its mobilization to pathogenic bacteria takes 
place is essential for efforts to control the dissemination of these genes. Here, we 
will discuss the concept of the resistome, provide examples of HGT of clinically 
relevant ARGs and present an overview of the current knowledge of the 
contributions the various HGT mechanisms make to the spread of antibiotic 
resistance. 
 
  
Dissemination of antimicrobial resistance in microbial ecosystems 
 
19 
Introduction 
The ever-increasing magnitude of antimicrobial resistance (AMR) encountered 
in human pathogens is a huge concern for public health worldwide, limiting 
treatment options for bacterial infections and thereby reducing clinical efficacy 
while increasing treatment costs and mortality. With a lack of development of 
new antibiotics, and increasing resistance even to last-resort antibiotics [1], there 
is a need to conserve the ones available. 
Natural antibiotics have existed for billions of years [2-5], providing a selective 
benefit for the producing strains by inhibiting or eliminating other bacteria 
competing for resources [6, 7]. Additionally, their function as cell-cell signalling 
molecules has been described [8, 9]. Just as antibiotics are ancient, so are 
antibiotic resistance genes (ARGs), as evidenced by studies identifying various 
ARGs in ancient permafrost samples [10, 11] and isolated cave microbiomes [3]. 
Resistance to antibiotics can occur either by mutations or by acquisition of 
resistance conferring genes via horizontal gene transfer (HGT), of which the latter 
is considered to be the most important factor in the current pandemic of 
antimicrobial resistance. 
The HGT of ARGs also far predates the production and use of antibiotics by 
humans. For example, OXA-type β-lactamases were found to be plasmid-borne 
and able to transfer between bacterial species millions of years ago [2]. However, 
while antibiotic resistance and its spread by HGT are ancient mechanisms, the rate 
at which these processes occur and the number of resistant strains has increased 
tremendously over the past few decades because of selective pressure through 
human antibiotic use. 
 
The global antibiotic selection pressure 
While the discovery of antibiotics revolutionized the field of medicine, their 
increasingly large-scale production and consumption has had widespread effects 
on the microbial biosphere. In their analysis, Van Boeckel et al. showed that global 
human antibiotic consumption amounted to 54,083,964,813 standard units (pills, 
capsules, or ampoules) in 2000 and had increased by 36% to 73,620,748,816 
standard units by 2010 [12]. The same authors estimated that antibiotic 
consumption in food animals, which is assumed to be larger than that of humans, 
was over 63 million kg in 2010 and will also drastically increase in the coming 
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years [13] despite recent initiatives to reduce antibiotic use in animals. Such high 
and continuously increasing amounts of antibiotics overwhelm the natural 
production, causing a constantly increasing selection pressure on bacterial 
populations in all exposed environments. 
The use and misuse of antibiotics in medicine, agriculture, and aquaculture has 
been linked to the emergence of resistant bacteria in these settings [14-16]. 
However, the impact of antibiotic usage extends further, as antibiotic residues, 
resistant bacteria, and genetic resistance elements subsequently spread to 
adjacent environments. The majority of consumed antibiotics are excreted 
unchanged [17] and are then introduced into the environment directly or through 
waste streams. Such waste streams, as well as wastewater treatment plants, are 
considered to be hotspots for the dissemination of AMR, since resistance genes, 
mobile genetic elements (MGEs), and (sub-inhibitory) antibiotic selection pressure 
from various sources are introduced to commensals and pathogens [18-21]. 
Moreover, the antibiotic compounds are often not completely removed in 
treatment plants [22, 23], from where they then disseminate further. A study by 
Larsson et al. showed that a treatment plant in India, receiving water from drug 
manufacturing sites, exposes its direct environment to very high levels of 
antibiotics, discharging approximately 45 kg of ciprofloxacin per day [24], 
contaminating surface, ground, and drinking water in the area [25]. Consequently, 
not only were highly multiresistant bacteria found to be common within the 
treatment plant [26], but high levels of ARGs and MGEs were also detected in 
nearby river sediments [27]. 
How environmental exposure to antibiotics contributes to the selection of 
resistant strains and the increase of resistome elements is illustrated by a study 
comparing soil samples taken between 1940 and 2008, which shows that ARGs 
from all classes of antibiotics tested (beta-lactams, tetracyclines, erythromycins, 
and glycopeptides) significantly increased since 1940, with a tetracycline ARG 
being over 15 times more abundant than in the 1970s [28]. Moreover, the 
increasing selection pressure has altered bacterial HGT processes, increasing the 
number of resistome elements which reside on mobile DNA compared to the pre-
antibiotic era [29]. 
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Reservoirs of resistance 
In order to understand the dissemination of antibiotic resistance, it is 
necessary to map the resistomes of various environments, and to unravel the 
extent to which these environments act as reservoirs for the dissemination of 
ARGs to bacterial pathogens. In recent years there has been increasing interest in 
this matter, as many studies have used various techniques to sample the 
resistome of environments such as, but not limited to, soil, wastewater, and 
human and animal gut microbiota. [30-33]. It has become clear that ARGs, 
including clinically relevant ones, are widespread in such environments [34]. 
Studies applying a metagenomic approach directly recover DNA from all 
microorganisms in a biological sample, thereby avoiding the bias that is 
introduced when selecting certain organisms and allowing for the investigation of 
the resistome of microbial ecosystems. The sequencing of metagenomes from 
various environments has provided a wealth of data which is often publicly 
available in databases. Such databases can be mined for the presence of 
resistance genes, even when the initial studies did not focus specifically on ARG 
content in these metagenomes. For example, mining such metagenomic 
databases for the plasmid-mediated colistin resistance gene mcr-1, which has 
recently been discovered in clinical and commensal isolates [35, 36], has revealed 
that this gene had already spread to the human gut microbiome of Chinese 
subjects several years ago [37]. While sequence-based studies provide huge 
amounts of data, they are limited to either identifying genes that are already 
known, or to predicting novel sequence functions based on high homology to 
known sequences. Annotation by sequence-based studies will keep increasing 
however, as studies using functional metagenomics keep identifying novel ARGs. 
Such studies have revealed a huge number of previously unknown ARGs present 
in environments such as soil [11, 38-42] or activated sludge [43, 44], as well as in 
the microbiota of animals [45, 46] and humans [47-53].  
Recent metagenomic studies have also uncovered that ARGs predominantly 
cluster by ecology, implying that the resistome in soils and wastewater treatment 
plants differ significantly from that of human pathogens [54, 55]. Nonetheless, the 
authors of these works note that parts of these resistomes are shared [56] and 
stress the importance of continuing to explore the resistome of such 
environments.  
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That commensals and the environment are important reservoirs for resistance 
is supported by several examples of ARGs on MGEs in human pathogens that 
appear to have originated from those reservoirs. A well-known example is that of 
the blaCTX-M genes, which have become the most prevalent cause of extended-
spectrum β-lactamases (ESBLs) in Enterobacteriaceae worldwide and a major 
cause of clinical treatment problems [57]. The potential origin of these genes was 
identified as the chromosomal DNA of various environmental Kluyvera species, 
from where they spread successfully to different bacterial species [58]. 
Shewanella algae, a marine and freshwater species, was found to be the origin of 
plasmid-encoded qnrA genes, conferring quinolone resistance [59], and different 
Vibrionaceae species might be the reservoir for other plasmid-encoded qnr genes 
[60], which have disseminated globally in various enterobacterial species, with 
exceptionally high prevalence rates in some areas  [61]. The OXA-48-type 
carbapenem-hydrolysing β-lactamase genes, which are increasingly reported in 
enterobacterial species worldwide, were also found to originate from the 
chromosomes of waterborne, environmental Shewanella species [62]. As with 
these few examples, many clinically relevant resistance genes are believed to 
have originated from non-pathogenic bacteria, highlighting the immense potential 
of HGT to enable these pathogens to overcome human antibiotic use. 
 
Contribution of the various HGT mechanisms in the spread of 
ARGs 
Conjugation 
Conjugation is the transfer of DNA through a multi-step process requiring cell 
to cell contact via cell surface pili or adhesins. It is facilitated by conjugative 
machinery which is encoded either by genes on autonomously replicating 
plasmids or by integrative conjugative elements in the chromosome [63, 64]. 
Additionally, this conjugative machinery may enable the mobilisation of plasmids 
that are non-conjugative, as observed for e.g. the exceptionally broad host range 
IncQ plasmids [65]. Of the various mechanisms that may facilitate HGT (Figure 1), 
conjugation is certainly the most commonly studied [66, 67]. 
ARGs are often associated with conjugative elements such as plasmids and 
transposons. While the transfer of these elements may also occur through 
transformation or transduction, conjugation is often considered as the most likely 
Dissemination of antimicrobial resistance in microbial ecosystems 
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responsible mechanism. This is due to the fact that it provides better protection 
from the surrounding environment and a more efficient means of entering the 
host cell than transformation, while often having a broader host range than 
bacteriophage transduction. Moreover, while conjugation is a process directed 
towards the transfer of bacterial genes, transfer of bacterial DNA by transduction 
is a side-effect of erroneous bacteriophage replication [67]. 
The conjugation of MGEs conferring antimicrobial resistance has been 
observed in many types of ecosystems, ranging from transfer between bacteria in 
insects, soil, and water environments to various food and healthcare associated 
pathogens [68]. Importantly, transfer of plasmids and conjugative transposons, 
such as those of the Tn916 family, between unrelated bacteria over large 
taxonomic distances has been described [69-72], indicating that this mechanism 
contributes to the dissemination of ARGs between different reservoirs via such 
broad host range MGEs.  
The spread of antibiotic resistance plasmids in human pathogens is especially 
well studied, and shows that once resistance genes have become established on 
successful plasmids, they can spread rapidly between strains, species, and even 
genera. This is well demonstrated by the blaCTX-M ESBL genes, which have 
disseminated to various narrow and broad host range plasmids within 
Enterobacteriaceae,  as well as to other opportunistic human pathogens [73]. 
These genes are now ubiquitous in humans [74], animals and the environment 
[75]. Furthermore, the transfer of plasmids in pathogens has led to the worldwide 
spread of numerous ARGs encoding resistance to β-lactams, quinolones, 
aminoglycosides, tetracyclines, sulfonamides, colistins and many other drug 
classes [76]. Of particular concern is the increasingly reported spread of plasmids 
harbouring carbapenem resistance [77] and the recent discovery of plasmid-
encoded colistin resistance in China [35], which has now already been identified 
at multiple continents [36] and may cause Enterobacteriaceae to truly become 
pan-drug resistant. Moreover multiple ARGs are often co-localised on the same 
plasmid, which allows for the relatively easy spread of multidrug resistance.  
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Figure 1: Mechanisms of horizontal gene transfer.  
Each quadrant represents one different method of gene transfer. (A) Conjugation  is a 
process requiring cell to cell contact via cell surface pili or adhesins, through which DNA is 
transferred from the donor cell to the recipient cell. (B) Transformation is the uptake, 
integration, and functional expression of naked fragments of extracellular DNA. (C) 
Through specialized or generalized transduction, bacteriophages may transfer bacterial 
DNA from a previously infected donor cell to the recipient cell. During generalized 
transduction, bacterial DNA may be accidentally loaded into the phage head (shown as a 
phage with a red DNA strand). During specialized transduction, genomic DNA 
neighbouring the prophage DNA is co-excised and loaded into a new phage (not shown). 
(D) Gene transfer agents (GTAs) are bacteriophage-like particles that carry random pieces 
of the producing cell’s genome. GTA particles may be released through cell lysis and 
spread to a recipient cell. 
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Transformation 
In 1928, Griffith became the first to demonstrate direct genetic exchange 
between different strains of Streptococcus pneumoniae [78]. Certain bacteria 
appeared to be capable of uptake, integration, and functional expression of naked 
fragments of extracellular DNA, a process called (natural) transformation. It soon 
became clear that bacteria could use transformation to evade antibiotics, by 
exchanging ARGs. In 1951, Hotchkiss induced penicillin and streptomycin 
resistance in previously sensitive strains of S. pneumoniae by exposing them to 
DNA from resistant strains [79]. Alexander et al. furthered this work by 
demonstrating intra- and inter-species transfer of streptomycin resistance 
between H. influenzae, H. parainfluenzae, and H. suis [80, 81]. 
In order for transformation to take place, several conditions have to be met. 
There must be DNA present in the extracellular environment; the recipient 
bacteria must be in a state of competence; and the translocated DNA must be 
stabilised, either by integration into the recipient genome, or by recircularisation 
(in the case of plasmid DNA) [82]. Whereas Neisseria spp. are considered to be 
constitutively competent [83, 84], other bacterial species capable of natural 
transformation may develop competence only under certain conditions, such as 
the presence of peptides or autoinducers, nutritional status, or other stressful 
conditions, as reviewed in more detail by Johnston et al. [84]. Importantly, studies 
have shown that exposure to antibiotics can induce competence in many species 
of bacteria, meaning that antibiotics would not only select for resistant strains, 
but also stimulate transformation of their ARGs [85-87].  
In vitro experiments have done much to elucidate transformation of ARGs. 
Early work proved that ARGs could be transformed; to this end, streptomycin, 
rifampicin, erythromycin, nalidixic acid and kanamycin resistance have variously 
been transformed into Neisseria gonorrhoeae [83], Bacillus spp. [88], 
Gallibacterium anatis [89], and Streptococcus pneumoniae [87]. The introduction 
of molecular techniques allowed for the identification of the ARGs being 
transformed. In vitro studies have shown that the genes parC and gyrA are 
involved in the transformation of fluoroquinolone resistance between 
Streptococcus pneumoniae [90] and several viridans streptococci [91, 92], and 
that transformation of penA confers penicillin resistance in commensal Neisseria 
species (N. flavescens and N. cinerea) and N. meningitidis [93]. 
Molecular techniques have also made it possible to look for evidence of 
transformation outside of the laboratory. Spratt et al. identified the penA variant 
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responsible for penicillin resistance in clinical isolates of N. gonorrhoeae [94]; 
sequence analysis revealed a mosaic structure, with blocks homologous to 
susceptible-type penA and blocks that diverge significantly [95]. These ‘resistant 
blocks’ could be traced back to a strain of N. flavescens that had been isolated in 
the pre-antibiotic era, suggesting that such commensal species could have been 
the original source for the now ubiquitous resistance to penicillin [96, 97]. Mosaic 
genes are formed when sections of foreign DNA are incorporated into a recipient 
genome, as is the case in transformation. Their presence implies that HGT has 
taken place [98]. In streptococci, the mosaic penicillin-binding protein (PBP) genes 
that encode PBPs with decreased affinity for β-lactam antibiotics are believed to 
be the result of gene transfer from related penicillin-resistant species [99] and 
have disseminated penicillin resistance between various streptococcal species 
[100]. Studies of fluoroquinolone resistance have demonstrated that mosaic 
variants of the genes parC, parE and gyrA are readily transformed between S. 
pneumoniae, S. mitis and S. oralis [101], and between S. pyogenes and S. 
dysgalactiae [102]. 
Mao et al. developed a technique to extract intra- and extracellular DNA 
separately from environmental samples, and applied it to samples from a river 
basin in China. The result – a greater abundance of DNA outside of cells than 
inside – implies that in certain environments, extracellular DNA is a large reservoir 
for genes which may be accessible via transformation [103]. Furthermore, 
Domingues et al. demonstrated that MGEs such as transposons, integrons and 
gene cassettes can be disseminated efficiently between species, regardless of 
their level of genetic relatedness [104]. Similarly, streptococcal species have been 
shown to exchange conjugative transposons via transformation in addition to 
conjugation [105]. All of this indicates that transformation provides a broad 
capacity for the horizontal spread of resistance elements between divergent 
species. 
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Transduction 
Bacteriophages play an important role in shaping the bacterial microbiome in 
any environment. Through specialized or generalized transduction, 
bacteriophages can transfer genes that are advantageous to their microbial hosts, 
in turn promoting their own survival and dissemination [106]. The transferable 
DNA sequences range from chromosomal DNA to MGEs such as plasmids, 
transposons and genomic islands [107].  
The mobilization or transfer of ARGs by bacteriophages has been documented 
for various bacterial species: the transduction of erythromycin [108], tetracycline 
or multiple resistances between strains of Streptococcus pyogenes [109]; the 
transfer of tetracycline and gentamicin resistance between enterococci [110]; the 
carriage of β-lactamase genes by bacteriophages in Escherichia coli [111] and 
Salmonella [112]; or the transfer of antibiotic resistance plasmids in MRSA [113].  
Recent studies applying metagenomic approaches to samples from various 
environments have suggested that bacteriophages may play a bigger part in the 
spread of ARGs than previously recognized. Colomer-Lluch et al. used qPCR to 
show that the β-lactam ARGs blaTEM, blaCTX-M and mecA were present in 
bacteriophages from river and urban sewage water samples. Additionally, cloning 
of the phage DNA into ampicillin susceptible E. coli hosts resulted in resistant 
transformants, harbouring either the blaTEM, blaCTX-M or undetermined ARGs [114]. 
In another study, the presence of ARGs in bacteriophages was detected in 
respiratory tract DNA of cystic fibrosis patients [115]. Modi et al. demonstrated 
that treatment with antibiotics increased the number of ARGs in the intestinal 
phageome of mice and expanded the interactions between phage and bacterial 
species [106], which is an important observation considering the increased 
environmental exposure to antibiotics discussed earlier. Furthermore, several 
studies have used qPCR to detect ARGs in bacteriophages from wastewater 
samples [116, 117], animal and human faecal samples [118, 119], wastewater and 
sludge derived from wastewater treatment plants [120], and hospital and 
wastewater treatment plant effluents [121], indicating that bacteriophages are 
significant reservoirs of ARGs. Shousha et al. investigated bacteriophages isolated 
from chicken meat and found that about a quarter of the randomly isolated 
bacteriophages were able to transduce resistance to one or more antibiotics into 
an E. coli host. Moreover, they found a significant relationship between the 
presence of bacteriophages transducing kanamycin ARGs, and E. coli isolates 
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resistant to kanamycin, implying a possible role of this mechanism in the spread 
of AMR [122]. 
Considering certain bacteriophages have been reported to have a wide host 
range that crosses between different species [110] or even different taxonomic 
classes [123], the observation of the plethora of ARGs carried by bacteriophages 
in various bacterial communities and environments provides renewed insights 
into the role of transduction in the dissemination of ARGs in microbial 
ecosystems. 
 
Gene transfer agents 
Gene transfer agents (GTAs), first identified in Rhodobacter capsulatus (RcGTA) 
in 1974 [124], are host-cell produced particles that resemble bacteriophage 
structures, capable of transferring genetic content. GTAs have several 
characteristic features: (i) rather than carrying DNA encoding their own machinery 
(as with self-propagating bacteriophages), GTAs carry random pieces of the 
producing cell’s genome [124-127]; (ii) the amount of DNA packaged by the GTAs 
is insufficient to encode all of their protein components, making them unable to 
self-propagate [128-130]; (iii) GTA production is controlled by cell regulatory 
mechanisms [130-133]; (iv) GTA particles are released through cell lysis [126, 134] 
although cultures do not display observable lysis [124] as only a small 
subpopulation of GTA-producing cultures (~3%) is responsible for ~95% of GTA 
release [126, 135]; (v) recently, it has been proposed that GTAs combine key 
aspects of transduction and transformation for cell entry, requiring proteins 
involved in natural transformation [136]. 
Although GTA particles do not necessarily carry any GTA-encoding genes [137],  
RcGTA-like gene clusters are widespread in alphaproteobacteria, especially in the 
Rhodobacterales: a complete set of RcGTA-like structural genes has been 
demonstrated in nearly every sequenced member of the Rhodobacterales [128, 
137]. Moreover, two species in the order of Rhodobacterales, Roseovarius 
nubinhibens and Ruegeria mobilis, are known to produce GTAs, and there is 
evidence of GTA production in Ruegeria pomeroyi [137-139]. Other known GTAs 
are VSH-1 in the spirochaete Brachyspira hyodysenteriae, Dd1 in the 
deltaproteobacterium Desulfovibrio desulfuricans, and VTA in the archaeon 
Methanococcus voltae [128, 137]. The genes required for GTA-production are 
contained within the host genome and appear to have been propagated through 
vertical transmission [128].  
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It has been suggested that GTAs have several advantages over the previously 
described mechanisms of HGT [125]: GTA particles afford DNA protection from 
damaging environmental factors, as opposed to the naked DNA involved in 
natural transformation; compared to conjugation, the transfer ability of GTAs is 
likely maintained after conditions killing the host cell, and is moreover not 
constrained by cell-to-cell contact; lastly, compared to transduction, GTA particles 
predominantly carry random pieces of host genome, rather than mostly 
bacteriophage DNA. In the marine environment, GTA-mediated transfer events 
have been reported to be remarkably high; up to several million times higher than 
previous estimates of HGT in marine environments, exceeding previously 
described transformation and transduction frequencies [138]. Moreover, genes 
can be exchanged between bacterial phyla [137, 138], suggesting the possible 
widespread contribution of GTAs in shaping and driving adaptation of the natural 
environment.  
In culture, GTA mediated transfer of antibiotic resistance markers has been 
readily demonstrated in Rhodobacter capsulatus [124, 140, 141] and the 
spirochaete Brachyspira hyodesenteriae [142, 143]. Moreover, GTAs have been 
used to transfer traits from plasmids [144]. In addition, the Brachyspira 
hyodesenteriae GTA VSH-1 can be induced by certain antibiotics [142], which 
points out its possible impact in its natural environment, the swine intestinal 
tract. Other Brachyspira spp. occur in the intestinal tract of other species, 
including humans and chickens [145], in which VSH-1 genes have been described 
[146]. However, interspecies GTA-mediated transfer remains to be demonstrated 
[146].  
The impact of GTAs on human health has yet to be established, but given the 
high frequency of transfer events in certain environments, and their ability to 
exchange genes between phyla, their potential to act as vehicles of resistance 
traits in the environment, and within the microbiota of humans and farmed 
animals is an area worthy of further study. 
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Conclusion 
The unprecedented increase in environmental levels of antibiotics, driven by 
medical and agricultural demand has disrupted the natural balance between 
microbes and antimicrobials. The effects this has on microbial communities are 
wide-ranging, and the result is an increasingly tangible threat to healthcare, as 
resistance to all known antibiotics disseminates rapidly around the globe. Our 
understanding of the interactions between antimicrobials and resistance against 
it, observed not only in the clinic but across different ecosystems around the 
world, is increasing rapidly and has provided valuable insights. However, it is vital 
that we continue to unravel the extent of, and dissemination between resistomes 
of these microbial ecosystems, as any attempt at coming to terms with the 
antimicrobial resistance problem will have to account for these vast reservoirs of 
ARGs.  
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Abstract 
Aim: 
We investigated the longitudinal development of several antibiotic resistance 
genes (ARGs) of the infant gut resistome during the first months after birth. 
Materials & methods: 
Faecal samples from 120 infants collected at the ages of 5, 13 and 31 weeks 
were analysed and subjected to qPCR for the detection of several ARGs. 
Results: 
The prevalence of ARGs significantly increased for ermB, tetM and tetQ, while 
it decreased for aac(6’)-aph(2”). Birth-mode and breastfeeding duration 
significantly affected tetQ prevalence. Correlations to bacterial taxa suggest that 
fluctuations in some ARGs are (partly) attributed to shifts in bacteroides 
colonization rates. 
Conclusion: 
Acquisition of ARGs in the gut microbiota occurs shortly after birth and 
resistome composition fluctuates over the course of several months, reflecting 
changes in microbial community structure.   
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Introduction 
Antimicrobial resistance (AMR) is one of the major public health threats that 
we currently face worldwide. AMR limits clinical treatment options for bacterial 
infections and thereby reduces clinical efficacy and increases treatment costs and 
mortality. In the past decades, most research on AMR has been focused on 
resistance in clinically relevant pathogenic bacteria, greatly enhancing our 
understanding on the prevalence and distribution of the AMR in these pathogens. 
However, over the last couple of years, a growing interest has emerged for the 
entire collection of antibiotic resistance genes (ARGs) within microbial 
ecosystems; the resistome.  
Bacterial communities such as the gut or soil microbiome are considered 
reservoirs of ARGs, where resistance in one bacterial species has the potential to 
spread to other, possibly pathogenic, bacteria as a result of horizontal gene 
transfer (HGT) [1, 2]. Studies have in fact shown that human pathogens and 
environmental bacteria share similar resistance genes [2-4]. Moreover, several 
resistance genes that currently cause major problems in the clinical treatment, 
such as the blaCTX-M or blaOXA-181 (a blaOXA-48 derivative) genes, originate from 
environmental bacteria [5-7]. 
The human gut microbiome harbours numerous functional antibiotic 
resistance genes [8, 9], which have the potential to disseminate to other 
potentially harmful bacteria in the gut. Due to its high density of microorganisms, 
the indigenous microbiome is considered to be a highly accessible reservoir of 
antibiotic resistance [10], where HGT interactions may be frequent. Also, the 
gastrointestinal tract is constantly exposed to numerous bacteria from the 
environment, e.g., food, water, soil, other humans, or animals, which often 
harbour ARGs [11].  
It has been shown that ARGs are present within the gut microbiota from early 
life and without any previous antibiotic exposure [12-14]. However, data on how 
the gut resistome develops and how it is influenced is limited. Colonization of the 
gut starts as soon as amniotic membranes rupture, and has even been suggested 
to already take place in utero [15]. Its composition fluctuates rapidly for several 
years and is influenced by many different factors, such as the mode of delivery, 
type of infant feeding, gestational age and antibiotic use by the infant [16]. 
Changes to the developing microbiota may also permanently alter its associated 
resistome. In order to gain better insight into the early development of the human 
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gut resistome and the potential deterministic factors, the aim in this study was to 
assess the prevalence of several ARGs in the gut microbiome of infants, over the 
course of the first several months following birth. 
 
Materials & Methods 
Study population 
The present study was conducted within the context of a randomized, placebo-
controlled trial on the primary prevention of atopic dermatitis by oral 
supplementation of a bacterial lysate in very early infancy (registration no. 
ISRCTN60475069). The study was approved by the Charité Ethics Committee in 
2002, and informed consent was given by all parents. Exclusion criteria were 
antibiotic treatment or other medication before the first sampling point (5 weeks 
after birth), lymphocytopenia, thrombocytopenia or intensive care after birth. The 
design of this trial has been described in detail elsewhere [17]. 
In the present study, a random subset of 120 infants that were allocated to the 
placebo-group of that prospective cohort study was included. From week 5 until 
the end of week 31 postpartum, infants were orally supplemented with the 
placebo daily. Parents were asked to sample the infant’s faeces at the age of 5 
weeks (start of intervention), at 13 weeks, and at 31 weeks (end of intervention). 
Participants were provided with standard stool tubes with spoons attached to the 
lid (Sarstedt, Hilden, Germany) and instructed to collect the faecal sample before 
the next visit during which times samples were handed to the researchers. 
 
Stool processing and DNA extraction 
Processing and DNA extraction of the stool samples was performed as 
described previously [18]. Briefly, within 8 hours upon defecation, stool samples 
were 10-fold diluted in Crowser-medium (5 g of Lab Lemco [meat extract 3.0 g/L 
and Pepton 5 g/L] + 50 mL of Gycerol and 450 mL of H2O; pH 7.3) and then 
immediately stored at -80°C until further analysis. For the extraction of 
metagenomic DNA, 200 µl of diluted faeces was added to a 2-mL vial containing 
approximately 0.3 g of 0.1 mm glass beads and 1.4 mL of ASL buffer from the 
QIAamp DNA stool minikit (Qiagen, Hilden, Germany). Samples were disrupted in 
a mechanical bead beater at 5000 rpm for 3 minutes. Subsequently, the bacterial 
DNA was isolated from the samples with the QIAamp DNA stool mini kit, 
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according to the instructions provided by the manufacturer. The DNA was eluted 
in a final volume of 200 µL and stored at -20°C until further analysis. 
 
Real time PCR assays 
Real-time PCR was performed to detect genes conferring resistance to 
different classes of antibiotics. Included were the β-lactamase encoding gene 
cfxA, tetracycline resistance encoding genes tetM and tetQ, macrolide resistance 
encoding gene ermB, aminoglycoside resistance encoding gene aac(6’)-aph(2”) 
and quinolone resistance encoding gene qnrS. The 16S ribosomal DNA (rDNA) was 
amplified as a reference gene to normalize for the amount of bacterial DNA in the 
samples. All targets except for qnrS were amplified on a MyiQ™ Single-Color Real-
Time PCR Detection System (BioRad, Hercules, CA, USA) in 25 µl reactions 
containing 12.5 µl iQ™ SYBR® Green Supermix (BioRad) and 5 µl template DNA. 
The qnrS gene was amplified on a 7900HT Fast Real-Time PCR System (Applied 
Biosystems) in 25 µl reactions containing 12.5 µl ABsolute QPCR ROX Mix (Thermo 
Scientific, Waltham, MA, USA) and 10 µl template DNA. Primer sequences and 
concentrations, as well as cycling conditions and PCR efficiencies were as 
described earlier [19]. ARG abundance was calculated by transforming the CT 
value into an arbitrary unit copy number using the efficiency slope of the 
respective target. 
 
Statistical analysis 
The prevalence of a resistance gene was compared between the three 
different time points by using the McNemar’s test for paired samples. Univariable 
logistic regression analysis were used to test for the association between birth 
mode, breastfeeding duration, number of siblings, time of introduction to solid 
foods, exposure to day-care centres or antibiotics used (as independent variables) 
and the presence of antibiotic resistance genes (as the dependent variable).   
Data about the presence and abundance (counts in log10 Colony Forming 
Units) of the following key bacterial groups and species: Bacteroides fragilis 
group, bifidobacteria, Clostridium cluster I, Clostridium difficile, Escherichia coli 
and lactobacilli, were previously determined [18]. Chi square tests were 
performed to test for associations between colonization by these bacterial taxa 
and ARGs prevalence, when the colonization prevalence was between 25-75%. 
Mann-Whitney U tests were performed to determine associations of the 
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abundance of bacterial taxa and the presence of ARGs. Pearson correlation was 
used to investigate the correlation between concentrations of gut bacteria and 
the abundance of ARGs. All analyses were performed using IBM SPSS Statistics 
version 20 and results were interpreted as statistically significant when p<0.05. 
 
Results 
Study population 
Of the 120 infants included in this study, 61 (50.8%) were girls and 59 (49.2%) 
were boys. Twenty eight (23.3%) infants were delivered by C-section, while 92 
(76.7%) were born vaginally. The majority of infants had no older siblings (65.8%), 
while 25% and 9.2% had 1 or 2 older siblings respectively (see also Table S1). All 
but one of the infants were breastfed, with the duration ranging from 1 to 157 
weeks (median of 42 weeks) and most infants (94.2%) were introduced to solid 
foods before the last sampling time point (31 weeks). Eleven (9.2%) infants had 
started day-care before 31 weeks, while the other had not. The number of oral 
antibiotic prescriptions were recorded and resulted in 17 prescriptions for 14 
(11.7%) of the infants.  
 
Prevalence of ARGs in the weeks following birth 
Overall, the prevalence of ARGs gradually increased over the three time points 
(Figure 1). While the prevalence of cfxA showed a non-significant increasing trend, 
the ermB gene increased significantly from 25.0% to 55.0% (p<0.05). For tetM and 
tetQ, the prevalence increased from 76.6% and 43.3% respectively at week 5, to 
92.5% (p<0.001) and 55.8% (p<0.05) at week 31. Contrarily, a significant decrease 
was observed for the aac(6’)-aph(2”) gene. Furthermore, qnrS was detected in 
only 1 sample at both week 5 and 31, and was therefore not included in any 
statistical analysis. 
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Figure 1. Prevalence of ARGs at three time points following birth. * p<0.05 compared to 
5 weeks. ** p<0.001 compared to 5 weeks. # p<0.05 compared to 13 weeks. ## p<0.001 
compared to 13 weeks. 
 
Influence of population characteristics on ARG prevalence 
The impact of birth mode, duration of breastfeeding, introduction of solid 
foods, day-care, antibiotic use and the number of siblings on the prevalence of the 
ARGs were investigated and are shown in Table S1. Infants delivered by caesarean 
section showed a significantly lower prevalence of tetQ when compared to 
vaginally born infants at all three time points (Figure 2A, Table S1). The duration 
of breastfeeding also impacted the prevalence of the tetQ gene. At 31 weeks, 
infants breastfed for longer than 6 months showed a significantly lower 
prevalence of tetQ when compared to those breastfed for 0-6 months (Figure 2B, 
Table S1). Lastly, the number of older siblings showed an association with the 
prevalence of the cfxA gene at the age of 13 weeks, as the prevalence of this ARG 
increased from 16.5% for children with no siblings to 30.0% and 54.5% for 
children with 1 and 2 siblings respectively (p for trend = 0.005) 
Prevalence rates of the investigated ARGs at 31 weeks were not associated 
with any antibiotic prescriptions or day-care attendance, although these factors 
suffered from a low sample size of the respective groups (Table S1). Neither was 
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there a difference between the introduction of solid foods before or after 6 
months of age. In this study, one dizygotic twin pair was included. In a sensitivity 
analysis it was, however, shown that excluding one of both infants did not 
influence our results. 
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Figure 2. Correlation of ARGs with mode of delivery or breast feeding duration. (A) 
Prevalence of tetQ in the gut microbiome of infants delivered either vaginally (white bars) 
or by Cesarean (C)-section (black bars) at 5, 13 and 31 weeks postpartem. (B) Prevalence 
of tetQ in the gut microbiome of infants breastfed 0-26 weeks (white bars) or > 26 weeks 
(black bars). * p<0.05. ** p<0.001. 
 
Correlation of ARGs to microbial composition 
The prevalence of all tested ARGs was compared to the previously determined 
microbial compositions of the faecal samples. Firstly, colonization prevalence with 
the B. fragilis group bacteria (from here on referred to as bacteroides), 
bifidobacteria, clostridium cluster I, Clostridium difficile, Escherichia coli and 
lactobacilli was compared with the prevalence of ARGs. A clear positive 
association was found between colonization with the bacteroides and the 
prevalence of the tetQ gene (Figure 3A). The colonization with bacteroides was, to 
a somewhat lesser extent, also associated with the prevalence of cfxA (Figure 3B), 
and with that of the ermB gene only at 31 weeks (p<0.05, data not shown). 
Furthermore, the colonization with C. difficile was shown to be positively 
correlated with the prevalence of ermB and tetM only at 31 weeks (both p<0.05, 
data not shown).  
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Figure 3. Correlation of ARGs to colonization with bacteroides. Prevalence of the (A) tetQ 
and (B) cfxA genes in infant gut microbiota either uncolonized (white bars) or colonized 
(black bars) with bacteroides at 5, 13 and 31 weeks postpartum. * p<0.05. ** p<0.001. 
 
In order to more deeply define the observed correlations, the colonization 
abundance (log CFU per gram of faeces) of bacteroides and C. difficile positive 
samples was compared with the prevalence of their associated ARGs. For the 
bacteroides, a higher abundance correlated with the presence of tetQ at all three 
time points (all p<0.05, Figure S1A-C) and with cfxA at 5 and 13 weeks (both 
p<0.05, Figure S1D-F). The abundance of C. difficile was neither associated with 
the prevalence of ermB nor with tetM. Finally, the colonization abundance of the 
bacteroides was also compared to the abundance (copy numbers) of the ARGs. 
Again, for the tetQ gene, there was a correlation between these abundances for 
all three time points (all p<0.001, Figure 4A-C). For cfxA, a correlation was found 
only at 31 weeks (p<0.05, Figure 4D-F).  
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Figure 4. Correlation of bacteroides colonization rate to ARG abundance. Colonization 
rate of bacteroides in infant gut microbiota vs. the abundance of either tetQ (A-C) or cfxA 
(D-F) at 5 (A, D), 13 (B, E), and 31 weeks postpartem (C, F). CFU, colony forming units; AU, 
arbitrary units. 
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Discussion 
In this study we demonstrate that the longitudinal development of the gut 
resistome starts already at a very early age and strongly reflects changes in the 
microbial community structure. Changes in the presence or amount of certain 
ARGs were correlated with changes in the microbial composition, which sheds 
light on the cause of several of our findings. For example, we found that infants 
who were delivered by caesarean section showed a significantly lower prevalence 
of tetQ as compared to infants who were born vaginally. Previous studies have 
reported that the gut microbial composition of infants is affected by birth mode, 
Dominguez-Bello et al. showed that vaginal-delivered infants acquired bacterial 
communities resembling their own mothers’ vaginal microbiota, whereas infants 
delivered by C-section harboured bacterial communities that were most similar to 
those found on the skin surface [20]. Caesarean delivered infants are also believed 
to be exposed initially to bacteria originating from the hospital environment and 
health-care workers [21]. As a result, infants born via caesarean section are far 
less colonized with bacteroides [16, 18, 22].  The majority of clinical bacteroides 
harbour the tetQ gene [23-25], which may explain the high correlation found in 
this study for the abundances of this gene and bacteroides.  Over time, 
colonization rates with bacteroides for infants delivered via C-section seem to 
shift more towards the rates which are observed in vaginally delivered infants [18, 
22], which is also well reflected in the diminishing difference between tetQ 
prevalence with increasing age for the two birth modes found in our study. 
Because of the difference in origin of the microbiota between vaginally and 
caesarean delivered infants, it would have been interesting to perform analysis for 
ARGs on the vaginal and faecal microbiota of the mothers of these infants as well. 
Unfortunately, such samples were not available for this study. Such an 
investigation was performed by Alicea-Serrano et al.; who reported that tetQ was 
found in only 1 out of 8 of the maternal vaginal microbiota samples and none of 
the oral (n=10) or faecal (n=7) samples of either vaginally  or C-section delivered 
neonates [26]. However, oral and faecal samples in that study were taken 15 
minutes and 24 hours after birth respectively, which may be too short of a period 
for sufficient colonization to take place.  Also, inclusion of the maternal faecal 
microbiota analysis would be of interest in future studies investigating this 
relation, since it is an important source of bacteroides and tet genes. In a recently 
performed study however, it was shown that the gut resistome of healthy infant 
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twin siblings, in particularly with respect to β-lactam resistance genes, were 
significantly more similar to each other as compared to the resistome of their 
mother or unrelated infants [27]. 
Additionally, we found that infants who had been breastfed for longer than 6 
months had a lower prevalence of tetQ. Several studies have shown that microbial 
composition is affected by breastfeeding [16, 28-30] and data of the microbial 
composition of our study population shows, amongst others, decreased amounts 
of bacteroides for infants who were breastfed for a longer time period [18]. 
Interestingly, while the prevalence of tetQ in the infant microbiota increased from 
43% at 5 weeks to 56% at 31 weeks, prevalence for this ARG in adult faecal 
samples was found to be 100% in a study we performed previously [19]. While 
there is little other metagenomic prevalence data about tetQ, this suggests that 
the prevalence of this gene in the gut microbiota will continue to follow a rising 
trend. 
The cfxA gene was also found to correlate with bacteroides colonization, but to 
a lesser degree, which is in line with studies that report a lower prevalence of cfxA 
in these bacteria [23, 31] than is found for tetQ. Also, a dose-response 
relationship between the number of older siblings and the prevalence of the cfxA 
gene was observed at 13 weeks of age. While the effect of birth order on the 
developing microbiota is not yet extensively recognized, some studies have 
indicated that older siblings influence the infants’ microbiota [32, 33]. This effect 
was found to be especially pronounced in our study population, showing a higher 
amount of lactobacilli and bacteroides in the gut microbiota of infants with older 
siblings [18]. No correlation for tetQ with the number of siblings was found 
however, suggesting that the cfxA increase is also attributed to changes other 
than just those measured in the bacteroides. 
A limitation of the current study is that the data presented are from infants 
born in the same geographical area (city of Berlin). While this area represents a 
multicultural community and great diversity concerning lifestyle and social 
economic status, the results may not allow for generalizability to other areas. 
Also, while the bacterial groups and species which were targeted by qPCR for 
microbiota analysis are considered to represent the major colonizers at this early 
age [34], and should thus cover major developments in the microbiota, this 
method does not provide a comprehensive analysis of the microbiota. Lastly, the 
investigated ARGs were previously shown to be present in different bacterial 
species [35-37] and have a varying prevalence in adult gut microbiota [19]. While 
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these genes were monitored for their acquisition and as indicators of the flux in 
the paediatric resistome, they represent only a part of the immense resistome. 
Future studies should aim to include comprehensive analysis of the infant 
microbiome and resistome. 
Taken together, our results show that the ARGs that we measured fluctuate 
according to and at least partially as a consequence of the fluctuation of the gut 
microbiota during the first few months after birth. These results may serve as an 
indication of how the human gut resistome at such an early age is shaped to a 
large degree by the composition of the gut microbiota. The direct clinical 
consequences of the presence of these ARGs in the microbiome at current and 
later age are not entirely clear. However, these genes have been described to 
confer e.g. aminoglycoside resistance in enterococci and staphylococci [35, 38], β-
lactam resistance in Bacteroides and Prevotella [39], macrolide resistance in 
various species including enterococci, streptococci and Enterobacteriaceae [36, 
40] or tetracycline resistance in many species including Bacteroides and 
Enterobacteriaceae [23-25, 37]. Colonization with resistant bacteria poses a risk 
for subsequent infections with those bacteria [41, 42] and moreover, these genes 
are often located on mobile genetic elements and their spread between various 
species in the human microbiota has been described [43, 44]. These results 
combined with evidence of genetic transfer of ARGs show that already at a young 
age, the microbiome presents a large reservoir of ARGs. In this regard, it would 
also be useful to monitor for lower prevalent but potentially more clinically 
relevant ARGs such as ESBL or carbapenemase genes, since the risks of increasing 
rates of these genes are easier to interpret and could help to instigate 
interventions. It is for example not well understood whether caesarean delivery is 
a risk for higher prevalence rates of drug resistant opportunistic pathogens 
originating from healthcare environments, or whether geographical differences in 
ARG prevalence affect the resistome at an early age. 
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Conclusion 
Our study provides insights into the presence and fluctuations of several ARGs 
in infantile gut microbiota throughout the first months after birth. For some ARGs 
we were able to associate changes in their presence and load with that of the 
bacteria they are normally harboured by. This included differences in microbiota 
which have been observed as a result of different modes of delivery, for example. 
In order to increase our understanding of the development of the human gut 
resistome, further studies on the infant gut resistome including both commensal 
as well as clinically relevant ARGs will be essential. 
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Figure S1. Correlation of bacteroides colonization rate to ARG presence. Colonization  
rate of bacteroides in infant gut microbiome negative (-) or positive (+) for either tetQ (A-
C) or cfxA (D-F) at 5 (A, D), 13 (B, E) and 31 weeks postpartum (C, F). Whiskers and outliers 
are displayed according to the Tukey method. * p<0.05. ** p<0.001. CFU, colony forming 
units. 
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Abstract 
We investigated the effect of international travel on the gut resistome of 122 
healthy Dutch travellers by using a targeted metagenomic approach. Our results 
confirm high acquisition rates of the extended-spectrum beta-lactamase encoding 
gene blaCTX-M, as prevalence rose from 9.0% pre-travel to 33.6% post-travel 
(p<0.001). Additionally, the prevalence of quinolone resistance encoding genes 
qnrB and qnrS rose from 6.6% and 8.2% pre-travel to 36.9% and 55.7% post-travel 
respectively (both p<0.001). Travel to South-East Asia and the Indian subcontinent 
was associated with the highest acquisition rates of qnrS and both blaCTX-M and 
qnrS respectively. Associations between the acquisitions of the blaCTX-M and qnr 
genes were investigated, but showed that the acquisition of a blaCTX-M gene was 
not associated to that of a qnrB (p = 0.305) or qnrS gene (p = 0.080). These 
findings further support the increasing evidence that travellers are aiding in the 
spread of antimicrobial resistance. 
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Introduction  
Antimicrobial resistance (AMR) is a public health threat worldwide, which 
continues to limit clinical treatment options for bacterial infections. The majority 
of research on AMR has been focused on resistance in clinically relevant 
pathogenic bacteria. However, there is a vast and largely unexplored reservoir of 
resistance genes present in non-pathogenic bacteria living in the environment or 
as commensals [1-5]. Because of horizontal gene transfer (HGT) between 
microbes of diverse species and genera, antibiotic resistance mechanisms in one 
organism, whether or not it is a pathogen, have the potential to emerge in 
clinically relevant pathogens [6]. Several of such HGT interactions between 
clinically relevant pathogens and environmental species have been described. For 
example, the plasmid-mediated quinolone resistance encoding qnrA gene was 
found to originate from the chromosomes of the aquatic bacterium Shewanella 
algae [7]. Another well-known example is the extended-spectrum beta-lactamase 
(ESBL) encoding blaCTX-M gene, which originates from chromosomal genes of 
environmental Kluyvera species [8] and has now emerged as the most prevalent 
cause of plasmid-mediated ESBL. 
With the unpredictable and immense potential of these resistance reservoirs in 
mind, the human gut microbiota warrants special attention, due to its high 
density of microorganisms and high accessibility [9]. The gastrointestinal tract is 
constantly exposed to numerous bacteria from the environment, via e.g. food, 
water, soil and other humans or animals. These incoming bacteria often harbour 
antibiotic resistance genes [10], which may be transferred to the indigenous 
microbial communities through HGT, enriching the pool of available AMR 
elements in the gut microbiota. 
It is therefore important to conduct studies that focus on the AMR of the gut 
microbiome as a whole, the so-called ‘gut resistome’, by using culture-
independent metagenomic approaches [9]. These approaches avoid the bias that 
is introduced when selective culturing is applied, since approximately 80% of the 
gut microbiota is not cultivatable [11], and therefore allow for a more complete 
assessment of the resistome. 
Traveling to geographic areas with high rates of bacterial antibiotic resistance 
has been indicated as a risk factor for the acquisition of antibiotic resistant 
bacteria [12]. Studies performed in Australia [13] Sweden[14, 15] and The 
Netherlands [16] have shown that international travel is indeed a major risk factor 
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for colonization with ESBL-producing Enterobacteriaceae. Likely, these resistant 
strains are acquired from the environment during travel, e.g. through food 
consumption [17]. Since the human intestinal microbiome will come in contact 
with many different bacterial species from travel-related environments, the effect 
of international travel on AMR is most likely neither limited to opportunistic 
pathogens such as E. coli nor to ESBL-encoding resistance genes. 
In this study, we aimed to investigate the effect of international travel on the 
human gut resistome. By using a targeted (PCR-based) metagenomic approach, 
we were able to compare the presence and relative abundance of specific 
resistance determinants in the entire human gut microbiome before and after 
international travel. 
 
Materials and Methods 
Population and design 
Healthy long-distance travelers were recruited between November 2010 and 
August 2012 through travel clinics (EASE Travel Clinic & Health Support) located in 
the southern part of The Netherlands. Travelers consenting to participate were 
asked to collect a stool sample prior to and immediately after travel, along with 
records of the duration and destination of their travel, illnesses or complaints 
during travel, drug use and antibiotic usage within the 3 months preceding travel. 
The stool samples were sent in via regular mail, the same day of collection, and 
were further processed on the day of receipt.  A total of 122 travelers were 
included. 
The countries visited were categorized into geographic regions: South-eastern 
(SE) Asia (Asia excluding the Indian subcontinent and the Middle-East), the Indian 
subcontinent (Bangladesh, Bhutan, India, Nepal, Pakistan and Sri Lanka), Northern 
Africa (countries north of the equator), Southern Africa (countries south of the 
equator), Southern Europe, Central America and South-America. 
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Stool processing and DNA extraction 
Stool samples were 10-fold diluted in peptone/water (Oxoid, Basingstoke, 
United Kingdom) containing 20% (vol/vol) glycerol (Merck, Darmstadt, Germany), 
homogenized by vortexing and stored at −20°C until molecular analysis. 
For the extraction of metagenomic DNA, 200 µl of diluted feces was added to a 
2-mL vial containing 0.5 g of 0.1 mm zirconia/silica beads (BioSpec, Bartlesville, 
OK, USA), 4 glass beads (3.0-3.5 mm)(BioSpec) and 1.2 ml of lysis buffer from the 
PSP Spin Stool Kit (Stratec Molecular, Berlin, Germany). Samples were disrupted in 
a Magna Lyser device (Roche, Basel, Switzerland) in three cycles of 1 min. at a 
speed of 5500 rpm. Subsequently, metagenomic DNA was isolated from the 
samples with the PSP Spin Stool Kit, according to the manufacturer’s instructions. 
DNA was eluted in 200 µl elution buffer and stored at -20°C until further analysis. 
 
Real-time PCR assays 
Real-time PCR was performed to detect and quantify the β-lactamase encoding 
genes cfxA, blaCTX-M, and blaNDM, tetracycline resistance encoding genes tetM and 
tetQ, macrolide resistance encoding gene ermB, aminoglycoside resistance 
encoding gene aac(6’)-aph(2”) and quinolone resistance encoding genes qnrA, 
qnrB and qnrS. The 16S ribosomal DNA (rDNA) was amplified as a reference gene 
to normalize for the amount of bacterial DNA in the samples. 
The 16S rDNA, cfxA, tetM, tetQ, ermB and aac(6’)-aph(2”) targets were 
amplified on a MyiQ™ Single-Color Real-Time PCR Detection System (BioRad, 
Hercules, CA, USA) in 25 µl reactions containing 12.5 µl iQ™ SYBR® Green 
Supermix (BioRad) and 5 µl template DNA. Melting curves were checked for each 
sample in order to confirm amplification of the correct product. For every target, 
amplified PCR products of 10 random positive samples were separated by 
agarose-gel electrophoresis to control for purity and size of the amplicons. Finally, 
for all genes except for the 16S rDNA (due to expected heterozygous amplicons), 
these products were sequenced using the PCR primers and an ABI BigDye 
Terminator v1.1 Cycle Sequencing Kit. Sequencing data were obtained on an ABI 
3730 DNA Analyzer (Applied Biosystems, Foster City, CA, USA) and were analyzed 
by using NCBI’s Basic Local Alignment Search Tool (BLAST). 
The blaCTX-M, blaNDM, qnrA, qnrB and qnrS genes were amplified on a 7900HT 
Fast Real-Time PCR System (Applied Biosystems) in 25 µl reactions containing 12.5 
µl ABsolute QPCR ROX Mix (Thermo Scientific, Waltham, MA, USA) and 10 µl 
template DNA. The blaCTX-M assay allows for the identification of the various 
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phylogenetic groups by the use of four probes. The probes to detect blaCTX-M 
groups 1 and 2 were combined in one reaction, while the probe to detect blaCTX-M 
group 9, and a probe to detect all groups except for the CTX-M-1 group were 
combined in a second reaction. All primer and probe sequences, as well as PCR 
conditions for each target are displayed in Table 1. 
To determine the efficiency of the PCR assays, threshold cycle (Ct) values 
obtained from a series of 5 template DNA dilutions, of at least 3 different samples, 
were graphed on the Y axis versus the log of the dilution on the X axis. For blaNDM 
a clinical isolate was used since no positive stool samples were available. The PCR 
efficiencies were; 16S rDNA: 94.0%, cfxA: 99.0%, tetM: 97.6%, tetQ: 95.9%, ermB: 
95.5%, aac(6’)-aph(2”): 97.0%, blaCTX-M-1+2: 98.2%, blaCTX-M-9+2-8-9-25: 96.7%, blaNDM: 
98.4%, qnrA: 97.4%, qnrB: 101.0% and qnrS: 102.5%. 
PCR Detection limits were determined for blaCTX-M, qnrB and qnrS. Clinical 
isolates harboring these genes were suspended to a 0.5 McFarland solution, 
followed by 10-fold dilutions in sterile saline solution. Quantification of colony 
forming units (CFU) in the suspensions was achieved by inoculating blood agar 
plates (Oxoid, Germany) and counting the number of colonies after overnight 
incubation at 37°C. Next, 20 µl of the quantified suspensions were mixed with 180 
µl of stool sample and submitted to DNA extraction as described above. 
Subsequently qPCR was performed on extracted DNA to generate standard curves 
for quantification. For blaCTX-M, the detection limit was 12 to 40 CFU/PCR reaction. 
For both qnrB and qnrS the detection limit was 1 to 5 CFU/PCR reaction. 
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Statistics 
Differences in relative resistance gene abundances between pre-travel and 
post-travel samples were calculated for each traveler using the ΔΔCt method with 
a Pfaffl modification to correct for PCR efficiency 









referencereference
ettett
CTE
CTE
ratio
^
^ argarg [18], 
which is the standard method to measure the relative change in mRNA expression 
levels with real-time PCR. In this study however, rather than measuring mRNA 
expression levels; the relative amount of target DNA present was measured using 
this method. The 16S rDNA was used as the reference gene.  
For a better visualization of increases and decreases in gene abundances in 
graphs, abundance ratios were converted to a fold-change. To determine the 
overall abundance change of a resistance gene, ratios were log-transformed. A 
two-tailed one-sample t-test was used to test whether the mean log-ratio 
significantly differed from zero. 
The number of stool samples positive for a resistance gene post-travel was 
compared to the positive samples which were present pre-travel, by using the 
McNemar’s test for paired samples. Multivariable logistic regression analysis were 
used to test for the association between age, sex, travel destination and duration, 
traveler’s diarrhea and antibiotic use preceding travel (as independent variables) 
and the acquisition of antibiotic resistance genes (as the dependent variable).  The 
association between acquisitions of multiple resistance genes was determined by 
a chi-squared test. 
All analyses were performed using IBM SPSS Statistics version 20 and results were 
interpreted as statistically significant when p<0.05.  
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Table 1. PCR primer/probe sequences and additional PCR conditions to identify antimicrobial resistance genes in gut 
microbiota after international travel 
Primer/probe 
Sequence* 
5 - 3 
Final 
conc. 
(nM) 
Prod. 
size 
(bp) Cycling conditions Ref. 
16S-rDNA_F TGGAGAGTTTGATCCTGGCTCAG 500 526 95°C, 4m [19] 
16S-rDNA_R TACCGCGGCTGCTGGCAC 250  35x 95°C, 15s; 65°C, 60s  
cfxA_F TGACAGTGAGAGATTTGCTGC 300 150 95°C, 3m [20] 
cfxA_R GGTCAGCCGACATTTCCTCTT 300  40x 95°C, 15s; 60°C, 15s; 72°C, 30s  
tetM_F ACACGCCAGGACATATGGAT 300 126 95°C, 3m [20] 
tetM_R GGGAATCCCCATTTTCCTAA 300  40x 95°C, 15s; 57°C, 15s; 72°C, 30s  
tetQ_F CAAGGTGATATCCGCTCTGA 300 128 95°C, 3m [20] 
tetQ_R GGAAAATCGTTCTTCCAGCA 300  40x 95°C, 15s; 57°C, 15s; 72°C, 30s  
ermB_F AAGGGCATTTAACGACGAAACTG 300 438 95°C, 3m This 
study ermB_R ATTTATCTGGAACATCTGTGGTATG 300  40x 95°C, 20s; 60°C, 30s; 72°C, 40s 
aac6-aph2_F TTGGGAAGATGAAGTTTTTAGA 300 173 95°C, 3m [21] 
aac6-aph2_R CCTTTACTCCAATAATTTGGCT 300  40x 95°C, 15s; 57°C, 20s; 72°C, 30s  
CTX-M_F ATGTGCAGYACCAGTAARGTKATGGC 500 336 95°C, 15m [22] 
CTX-M_R ATCACKCGGRTCGCCNGGRAT 500  40x 95°C, 15s; 58°C, 20s;   
CTX-M-1 JOE-CCCGACAGCTGGGAGACGAAACGT-BHQ1 100  72°C, 30s  
CTX-M-2 6FAM-CAGGTGCTTATCGCTCTCGCTCTGTT-BHQ1 100    
CTX-M-9 JOE-CTGGATCGCACTGAACCTACGCTGA-BHQ1 100    
CTX-M-2-8-9-25 6FAM-CGACAATACYGCCATGAA-MGB-NFQ 100    
NDM_F ATTAGCCGCTGCATTGAT 400 154 95°C, 15m [23] 
NDM_R CATGTCGAGATAGGAAGTG 400  42x 95°C, 15s; 60°C, 60s  
NDM_probe 6FAM- CTG[+C]CA[+G]AC[+A]TT[+C]GGTGC-BHQ1 200    
qnrA_F CAGTTTCGAGGATTGCAGTT 400 148 95°C, 15m [24] 
qnrA_R CCTGAACTCTATGCCAAAGC 400  45x 95°C, 30s; 52°C, 30s;   
qnrA_probe 6FAM-AAGGGTGYCACTTCAGCTATGCC-BHQ1 100  72°C, 30s  
qnrB_F CAGATTTYCGCGGCGCAAG 400 134 95°C, 15m [24] 
qnrB_R TTCCCACAGCTCRCAYTTTTC 400  45x 95°C, 30s; 55°C, 30s;   
qnrB_probe 6FAM-CGCACCTGGTTTTGYAGYGCMTATATCAC-
BHQ1 
100  72°C, 30s  
qnrS_F TCAAGTGAGTAATCGTATGTA 400 157 95°C, 15m [24] 
qnrS_R GTCTGACTCTTTCAGTGAT 400  45x 95°C, 30s; 55°C, 30s;   
qnrS_probe 6FAM-CCAGCGATTTTCAAACAACTCAC-BHQ1 100  72°C, 30s  
*Nucleic acids between brackets and preceded by ‘+’ are locked nucleic acids; nM, nanomolar; conc., concentration; 
Prod., product; bp, base pairs; Ref., reference. 
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Results 
Study population 
A total of 122 travelers (71 women and 51 men) with a median age of 43 years 
(range, 18 to 72 years) were included. The median length of stay abroad was 21 
days (range, 5 to 240 days). Fourteen participants traveled for over 60 days, 5 of 
these exceeded a travel length of 120 days. Most participants visited one country, 
while 22 visited more than one country. Six participants visited more than one of 
the defined geographic regions (table 2) and 7 participants did not provide 
information concerning their destination. 
 
Table 2. Characteristics of the 122 travelers from the Netherlands 
 Median Range 
Age (years) 42.7 18-72 
Travel duration (days) 21.0 5-240 
   
 No. % 
Sex:  Female 71 58.2 
 Male 51 41.8 
Traveler’s diarrhea  45 36.9 
Antibiotic usage 15 12.3 
  
Region visited:  
 South-East Asia 28 23.0 
 Indian subcontinent 31 25.4 
 Northern Africa  16 13.1 
 Southern Africa  17 13.9 
 Southern Europe 6 4.9 
 Central America 4 3.3 
 South America 6 4.9 
 Other/multiple 7 5.7 
The countries included in respective regions are: SE Asia (Indonesia, 
Philippines, Malaysia, Myanmar, Cambodia, Thailand, Vietnam), 
Indian subcontinent (India, Nepal, Sri Lanka), Northern Africa (Canary 
Islands, Egypt, Gambia, Ghana, Togo, Morocco, Senegal, Uganda), 
Southern Africa (Namibia, Kenya, Tanzania, Zanzibar, Mauritius, 
South-Africa), Central America (Panama, Costa Rica, Mexico) southern 
America (Argentine, Bolivia, Brazil, Columbia, Peru, Suriname), 
Southern Europe (Croatia, Spain, Turkey), Other (Australia, Fiji, New 
Zealand, Oman). 
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Prevalence of resistance genes in stool samples 
Figure 1 presents the prevalence of the antimicrobial resistance determinants 
in stool samples from healthy volunteers (N=122) before and after international 
travel. The cfxA gene was detected in 111 pre-travel stool samples (91.0%) and in 
115 post-travel samples (94.3%). The extended spectrum beta-lactamase (ESBL) 
encoding blaCTX-M gene was prevalent in 11 pre-travel samples (9.0%), whereas the 
gene was detected in 41 samples after travel (33.6%), which was a statistically 
significant increase (p<0.001). Additionally, the post-travel samples of 5 
individuals contained blaCTX-M genes of two different phylogenetic groups, 
whereas pre-travel only a single CTX-M variant was detected for 2 of these 
individuals and blaCTX-M was undetected for the other 3 individuals. For 6 
individuals who were positive for the blaCTX-M gene pre-travel, the gene was not 
detected in the post-travel sample. The carbapenemase encoding gene blaNDM was 
not detected in any sample. 
The prevalence of both tetM and tetQ was found to be very high in the stool 
samples. The tetM gene was present in all pre-travel samples and all except for 
one post-travel sample (99.2%), while tetQ was detected in every sample. The 
ermB gene was also found to have a high prevalence in both pre- and post-travel 
samples (both 99.2%). The prevalence of the aac(6’)-aph(2”) gene was not altered 
by traveling; this gene was present in 79 pre-travel (64.5%) and 86 post-travel 
samples (70.5%).  
The quinolone resistance genes qnrA, qnrB and qnrS all had a relatively low 
prevalence of 0.8%, 6.6% and 8.2% respectively in the pre-travel samples. In the 
post-travel samples however, increases for all three genes were observed, as 
qnrA, qnrB and qnrS were detected in 3.3%, 36.9% and 55.7% of the samples 
respectively. For qnrB and qnrS, this was found to be significantly higher than pre-
travel (both p<0.001).  
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Figure 1. Prevalence (%) of antibiotic resistance determinants in stool samples from 
healthy Dutch travelers (N=122) pre- and post-travel. Statistical significance of the 
prevalence between the two groups was calculated using the McNemar’s test for paired 
samples and is denoted in the graph with ** (p<0.001). 
 
Relative gene abundances before and after travel 
Since the prevalence of the cfxA, tetM, tetQ and ermB genes were found to be 
very high in both pre-travel as well as post-travel samples; we compared the 
relative abundances of the genes between these samples for each traveler, in 
order to determine whether traveling influenced the gene abundance. 
For all four genes, the observed changes in gene abundance per traveler were 
distributed between both increases and decreases (Figure 2). Determining the 
overall increase or decrease of the abundance of each gene showed that none of 
the investigated genes was significantly changed in abundance after travel, 
neither per continent nor in total. 
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Figure 2. Relative fold changes in gene abundance post-travel compared to pre-travel 
for each of the 122 healthy Dutch travelers for genes cfxA (A), tetM (B), tetQ (C) and 
ermB (D). Increases are shown in white bars on the positive Y-axis, while decreases are 
shown in dark grey bars on the negative Y-axis. Each bar on the X-axis represents the 
change in a different volunteer. The travel destination regions of the volunteers are 
denoted above the graph. No region is indicated for some travelers who visited multiple of 
these regions or countries which did not classify in the displayed regions (see table 2). 
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Association of travel destination and other risk factors on gene 
acquisition 
The rate of acquisition of a blaCTX-M gene was highest for travelers visiting the 
Indian subcontinent (58.1%; p< 0.05, OR 26.22, 95%CI 2.86-240.38) (Table 3). 
Travel to other regions was associated with a blaCTX-M acquisition rate of 17.9% for 
SE Asia, 31.3% and 29.4% for Northern and Southern Africa respectively. In the 
combined Europe & America category, only 1 blaCTX-M acquisition was observed 
(6.3%), which was detected in a traveler who had been to Southern Europe 
(Turkey).  
The acquisition of the qnrB gene was not statistically significantly associated 
with travel to a specific region, whereas the acquisition of qnrS was highest for SE 
Asia (75.0%; p = 0.001, OR 15.74, 95%CI 3.13-79.24), followed by the Indian 
subcontinent (61.3%; p<0.05, OR 9.23, 95%CI 1.94-43.87). The acquisition rate 
was also elevated for Northern Africa (43.8%) and Southern Africa (35.3%), but 
was not significant. 
Furthermore, associations between age, sex, travel destination and duration, 
traveler’s diarrhea and antibiotic use preceding travel and the acquisition of 
resistance genes were investigated, but none were found (Table 3). 
 
Phylogenetic groups of blaCTX-M genes and association with qnr genes 
Of the total of 41 blaCTX-M genes acquired during travel, 24 belonged to the 
CTX-M-1 group, 2 belonged to the CTX-M-2 group, 6 were of the CTX-M-9 group 
and 9 were positive for the CTX-M-2-8-9-25-probe, but not for the CTX-M-2 or 9 
probe, indicating that these were groups 8 or 25. The CTX-M groups acquired per 
region are shown in table 4. In contrast, 9/11 CTX-M types detected in the pre-
travel samples belonged to the CTX-M-9 group and only 2/11 to the CTX-M-1 
group. 
Associations between the acquisitions of the blaCTX-M and qnr genes were 
investigated as well (table 5), but showed that the acquisition of a blaCTX-M gene 
was not associated to that of a qnrB (p = 0.305) or qnrS gene (p = 0.080). Neither 
was the gain of a blaCTX-M gene of the CTX-M-1 group, which was the dominant 
acquired type (58.5%), associated with the acquisition of either qnrB (p = 0.631) or 
qnrS (p = 0.256). 
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Table 3. Associations between (travel-associated) risk factors and acquisition rates of blaCTX-M, qnrB and qnrS 
among 122 healthy Dutch travelers 
 
No. 
travelers 
Travelers with gene acquisition 
blaCTX-M  qnrB  qnrS 
No. (%) OR (95%CI) † No. (%) OR (95% CI) † No. (%) OR (95% CI) † 
Region visited 
      Europe &   
      America‡§ 
 
 
16* 
 
1 (6.3)  
 
1.00 
 
6 (37.5) 
 
1.00 
 
3 (18.8) 
 
1.00 
      SE Asia 
 
28* 5 (17.9)  3.34 
(0.34-33.14) 
7 (25.0) 0.47 
(0.12-1.90) 
21 (75.0) 15.74 
(3.13-79.24) 
      Indian    
      subcontinent 
31* 18 (58.1) 26.22 
(2.86-240.18) 
10 (32.3) 0.71 
(0.18-2.71) 
19 (61.3) 9.23 
(1.94-43.87) 
      Northern   
      Africa 
16* 5 (31.3) 7.28 
(0.70-75.92) 
5 (31.3) 0.64 
(0.14-2.98) 
7 (43.8) 2.90 
(0.54-15.57) 
      Southern     
      Africa 
17* 5 29.4) 5.57 
(0.56-55.77) 
5 (29.4) 0.65 
(0.15-2.84) 
6 (35.3) 2.41 
(0.46-12.66) 
Age (years) 122  1.00  
(0.96-1.03) 
 1.01  
(0.98-1.04) 
 1.00 
(0.97-1.04)  
Travel duration 
(days) 
122  1.00  
(0.98-1.01) 
 1.00 
(0.99-1.02) 
 1.00 
(0.98-1.01) 
 
Sex  
71 
51 
 
25 (35.2) 
13 (25.5) 
 
1.00 
0.62  
(0.23-1.67) 
 
25 (35.2) 
15 (29.4) 
 
1.00 
1.06  
(0.44-2.57) 
 
41 (57.7) 
21 (41.2) 
 
1.00 
0.39 
(0.15-1.00) 
      Female‡ 
      Male 
Antibiotic use  
107 
15 
 
32 (29.9) 
6 (40.0) 
 
1.00 
1.44  
(0.40-5.25) 
 
35 (32.7) 
5 (33.3) 
 
1.00 
1.28  
(0.36-4.51) 
 
52 (48.6) 
10 (66.7) 
 
1.00 
1.64 
(0.43-6.22) 
      No‡ 
      Yes 
Traveler’s 
diarrhea  
 
77 
45 
 
20 (26.0) 
18 (40.0) 
 
1.00 
1.84 
 (0.70-4.82) 
 
25 (32.5) 
15 (33.3) 
 
1.00 
0.97  
(0.40-2.37) 
 
40 (51.9) 
22 (48.9) 
 
1.00 
0.65 
(0.26-1.63) 
      No‡ 
      Yes 
*Numbers do not add up to 122, because the 14 travelers visiting multiple or unknown regions were added to a 
remainder category not included in this table.  
†Odds ratios and 95% confidence intervals of the associations between risk factor and acquisition of resistance gene 
(negative pre-travel and positive post-travel) by multivariable logistic regression analysis. Models included the 
following variables: travel destination, age, travel duration, sex, antibiotic use within 3 months preceding the travel 
and traveler’s diarrhea. 
‡Reference category. 
§Europe and America, previously reported non-high risk regions, were pooled in order to establish an adequately sized 
reference category. 
Boldface indicates a significant result. 
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Table 4. CTX-M groups of the acquired genes during travels by 122 
Dutch travelers per region 
 CTX-M-group 
Region 1 2 9 8/25 
SE Asia 2 1 3 0 
Indian subcontinent 15 0 2 3 
Northern Africa 3 0 1 1 
Southern Africa 2 0 0 3 
Southern Europe 0 1 0 0 
Others 2 0 0 2 
     
Total 24 4 6 9 
 
Table 5. Associations between acquisitions of blaCTX-M and qnrB or qnrS 
during travels by 122 travelers from The Netherlands 
    qnrB acquisition  qnrS acquisition 
   no yes   no yes 
blaCTX-M 
acquisition 
no 59 25   46 38 
 70.2% 29.8%   54.8% 45.2% 
       
 yes 23 15   14 24 
  60.5% 39.5%   39.8% 63.2% 
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Discussion 
In this study, we describe the use of a metagenomic approach to study effects 
of international travel on (a part of) the resistome of the human gut microbiota. 
Our results provide insights in the prevalence of the investigated resistance genes 
in the human gut microbiota and demonstrate high acquisition rates of the ESBL 
encoding gene blaCTX-M and quinolone resistance encoding genes qnrB and qnrS as 
a result of international travel. Of note, the prevalence of these genes rose from 
9.0%, 6.6% and 8.2% pre-travel to 33.6%, 36.9% and 55.7% post-travel 
respectively.  
In the prospective cohort studies among Australian,[13] Dutch[16] and 
Swedish [14, 15] travelers, it was shown that international travel is indeed a risk 
factor for colonization with ESBL-producing Enterobacteriaceae, and that travel to 
India or the Indian subcontinent was the highest risk factor. These findings are in 
line with the acquisition rates of blaCTX-M, as found in our study, which were 
highest for travelers to the Indian subcontinent. 
The phylogenetic types of the blaCTX-M gene, which were acquired in our study 
group, were clearly dominated by CTX-M group 1, especially in the Indian 
subcontinent. This also corresponds with the earlier performed cohort studies 
which show that the colonization with ESBL-producing Enterobacteriaceae after 
travel to India or the Indian subcontinent are mainly those of CTX-M group 1 [13-
15]. While the power of our study was insufficient to conduct statistical analyses 
for the specific CTX-M groups, it was striking that acquisition of genes of the CTX-
M-2 group was detected twice and those of group 8 or 25 was detected 9 times. 
In previous studies, these CTX-M groups were not detected at all [13, 14], or only 
sporadically [15, 16]. The difference in results could potentially be caused by our 
use of a metagenomic approach, which might detect blaCTX-M in a much wider 
array of species than studies investigating specific cultured Enterobacteriaceae 
species.  This difference in approach might furthermore explain that of the blaCTX-M 
genes detected pre-travel in our study population, the majority (9/11; 81.8%) 
were of the CTX-M-9 group, which contrasts studies which report that blaCTX-M-15 
(which belongs to the CTX-M-1 group) is predominant in ESBL-producing 
Enterobacteriaceae in The Netherlands [16, 25, 26]. Aside from the different 
methodology used, it should also be noted, that the population size in these 
studies was larger than the one in our current study.  
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Plasmid mediated quinolone resistance (PMQR) genes such as the qnr variants 
provide low-level quinolone resistance. However, these genes are relevant since 
they facilitate the emergence of higher-level resistance and thus can speed up the 
development and spread of resistance to these antimicrobial agents [27]. While 
foreign travel has been associated with the acquisition of PMQR positive isolates 
[28-30], these genes have thus far not been focused on in prospective cohort 
studies investigating the effects of travel on antibiotic resistance. 
An interesting study by Vien et al. investigated the prevalence of the qnr genes 
in fecal swabs of children in Vietnam presenting with an acute respiratory tract 
infection [24], and showed a very high qnrS prevalence of 74.5%. Travel to areas 
with such a high prevalence could therefore well be a major risk factor for 
acquisition of these genes. Interestingly, 5 out of 6 (83.3%) participants in our 
study who had been to Vietnam during their travels had acquired a qnrS gene. In 
total, 11 volunteers had traveled to Cambodia, Thailand, Vietnam or a 
combination of these countries (which are geographically neighboring) and 9 
(81.8%) had acquired a qnrS gene. These data suggest that organisms carrying the 
qnrS gene have a high prevalence in these areas and that travelers visiting these 
areas have a high risk of being exposed to those organisms.  
Co-existence of qnr genes with various other resistance genes, such as blaCTX-M, 
on the same plasmid is a well-known phenomenon [31-34] and could play a role in 
the fact that both these type of genes were found to be more prevalent in our 
post-travel samples. However, no association between these genes was found in 
our samples. The qnrS gene was most often acquired by travelers who visited SE 
Asia, and to a lesser extend the Indian subcontinent, whereas the acquisition rate 
for blaCTX-M was clearly the highest for the Indian subcontinent, but was not found 
to be higher for SE Asia compared to other regions. This indicates that while travel 
to the Indian subcontinent is a high risk factor for acquiring both these genes, 
these risk factors are not necessarily related. 
While the use of a metagenomic approach has the advantage of being able to 
detect resistance in a much wider array of species compared to culturing 
methods, a limitation is that it is not yet known in which organisms the acquired 
resistance genes detected in our study are present, nor if they are being 
expressed. Another limitation of our study is that our population size was not 
large enough to perform a more extensive risk analysis. Future studies would 
benefit from larger population sizes in order to conduct more extensive analyses 
for risk factors such as antibiotic usage, travel destination and duration of travels. 
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Furthermore, in future studies it would be highly relevant to include a follow-up 
sampling of the traveling participants in order to also focus on investigating the 
time span that these acquired resistance genes remain in the resistome, and if the 
perseverance or even HGT of these genes in the resistome over time is promoted 
by e.g. selective pressure introduced by antibiotic usage. To date, little is known 
about the duration that resistant organisms acquired by travel remain in ones 
microbiota, while this plays a key role in the ability to further spread these 
organisms or resistance elements. 
By investigating several targeted resistance genes, it became evident that 
resistance genes from foreign environments are being introduced into the gut 
resistome at high rates as a result of international travel. While the consequences 
of these changes in the resistome are difficult to predict, the introduction of these 
genes into the genetic pool of resistance elements may create opportunities for 
the horizontal transfer to other organisms in the gut microbiota.  
In conclusion, our data demonstrate an increasing prevalence of blaCTX-M, qnrB 
and qnrS genes in the stools of healthy Dutch volunteers directly after they had 
been on an international travel. These findings contribute to the increasing 
evidence that travelers are aiding in the spread of antimicrobial resistance. 
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Abstract 
The human microbiome is an important reservoir of antimicrobial resistance 
genes, collectively termed the resistome. So far, few studies have examined the 
dynamics of the human gut resistome in healthy individuals. We aimed to provide 
insight into the dynamics of the human gut resistome by investigating the 
presence and abundance of several antimicrobial resistance genes (ARGs) in 
faecal samples of a group of healthy volunteers at three different time points. 
Moreover, we placed these normally occurring fluctuations into context of our 
previous findings on the shifts in the resistome of international travellers.  
Faecal samples from 23 healthy, non-travelling participants were collected at 
baseline and subsequently 2 and 4 weeks after inclusion. DNA was subsequently 
isolated from these samples and subjected to qPCR for the detection and 
quantification of several ARGs. 
For the highly prevalent ARGs cfxA, tetM, and ermB we found no significant 
differences in the fluctuations in abundance of our group compared to the group 
of travellers (p = 0.71, 0.18 and 0.91, respectively). For blaCTX-M and qnrB, a 
prevalence of 17.4% and 5.7% was observed (11.6% and 2.9% of all samples). In 
two cases acquisition of a blaCTX-M gene and in one case acquisition of a qnrB gene 
was observed during follow-up of the study. While no sample was positive for 
vanA or qnrS, very high rates of vanB (78.3%) were observed at all time points.  
In conclusion, we showed that fluctuations in the abundance of ARGs which 
are highly prevalent in the human gut microbiome is a common occurrence, not 
related to international travel. 
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Introduction 
Bacterial resistance to antimicrobials is a major concern in healthcare. Long-
time, vertical evolution within clinically relevant pathogens was thought to be the 
major cause of emerging antibiotic resistance. Research therefore mainly focused 
on resistance in pathogenic bacteria. However, there is a growing body of 
evidence that environmental and commensal bacteria comprise an enormous and 
mostly unexplored reservoir of antibiotic resistance genes (ARGs) [1-4]. Because 
of horizontal gene transfer (HGT) these genes are potentially transferable to 
bacteria of the same or other species and genera, including relevant pathogens [5, 
6]. For several clinically relevant resistance genes such transfer has actually been 
described [7-9].  
The human gut microbiome has gained special attention as reservoir of ARGs, 
potentially promoting the emergence of resistant pathogens [10-12]. The high 
density of microorganisms and biofilms in the gut in combination with its 
accessibility and constant exposure to various bacteria and genetic material from 
food, water, soil and even intestinal organisms from other hosts provide 
favourable conditions for resistance gene transfer to take place [11, 12]. The gut 
can therefore be described as a ‘genetic-genomic-metagenomic reactor’ [11]. In 
fact, sequencing of the gut metagenomes of 162 individuals revealed 1.093 ARGs 
in a total of 4.1 million scanned genes [4]. In addition to that, the ARGs ermB and 
b12e_cfxa, conferring resistance to respectively erythromycin and cephalosporin 
were found in nearly all samples. More recently, another study with 275 
individuals of different age groups and seven different nationalities revealed 
resistance to 53 antibiotics. Resistance genes to tetracycline (tetQ and tetM), 
bacitracin (bacA/ uppP and bcrA) and vancomycin (vanUG, vanG and vanRG) were 
found in nearly all gut metagenomes [13]. While metagenomic studies confirm 
richness and diversity of AGRs within the human gut microbiome, horizontal gene 
transfer of the ARGs in the gut microbiome has already been demonstrated in 
relatively small in vivo experiments between species of Enterococcus faecium [14] 
and species of E. coli  [15]. In addition, there is mounting evidence for the clinical 
importance of HGT in the lower gastrointestinal tract, including several case 
reports demonstrating the occurrence of  HGT in the gut of patients [16-21]. 
In a previous study of the gut resistome of 122 travellers from the Netherlands 
it was shown that international travel is associated with the acquisition of 
different ARGs genes. Moreover,  changes in the relative abundance of the 
Chapter 4B 
 
86 
tetracycline-, erythromycin- and ß-lactam resistance encoding genes tetM, ermB 
and cfxA between pre- and post-travel stool samples was observed   [22]. 
However, little is known about changes within the resistome that takes place 
without exposure to factors associated with the selection or acquisition of 
antibiotic resistance (e.g. international travel,  antibiotic usage). In this study we 
aimed to investigate normal longitudinal fluctuations in the abundance of several 
ARGs within the human gut metagenome of healthy volunteers and contrast them 
to previous findings in travelling individuals. 
 
Materials & methods 
Population and design 
Consenting healthy volunteers (> 18 years of age) were recruited between 
December 2014 and January 2015. Volunteers that had used antimicrobial agents 
in the past month or had travelled to regions outside Europe or North America in 
the past 3 months prior to the start of the study were excluded. Participants were 
asked to collect a total of 3 faecal samples at baseline and subsequently 2 and 4 
weeks after inclusion (T0, T1 and T2 respectively). At each collection time point 
subjects were asked to fill in a questionnaire on antibiotic- and/or probiotics 
usage, travelling behaviour and whether they experienced any episodes of 
diarrhoea (defined according to the WHO as the passage of 3 or more loose or 
liquid stools per day, or more frequently than is normal for the individual) in the 
past two weeks. Participants that used antibiotics/probiotics, experienced 
diarrheal episodes or travelled outside of a neighbouring country during follow-up 
were subsequently excluded  from the analysis. The faecal samples together with 
the questionnaires were sent by regular mail to the laboratory at the same day of 
collection or were admitted to a central collection point and were processed in 
the lab on the day of receipt. 
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Faecal specimen processing and DNA extraction 
Faecal samples remained at room temperature for a maximum of 48 hours, 
after which they were diluted 10-fold in a peptone/water solution (Oxoid, 
Basingstoke, UK) containing 20% glycerol (Merck, Darmstadt, Germany). After 
homogenizing by vortexing, samples were stored at -20 °C until extraction of DNA 
was performed. DNA extraction was performed as described earlier [22]. DNA 
samples were stored at -20 °C until molecular analysis.  
 
Real-time PCR 
Real-Time PCR was used to detect and quantify all resistance genes as 
described earlier [22]. In addition, a multiplex TaqMan assay for the detection of 
vanA and vanB and E. faecium genes was used for the detection of vancomycin 
resistance genes. Primer and probe sequences were as follows: 5’-
GCCGGAAAAAGGCTCTGAA-3’ (forward), 5’-TCCTCGCTCCTCTGCTGAA-3’ (reverse), 
5’-FAM-ACGCAGTTATAACCGTTCCCGCAGACC-BHQ2-3’ (probe) for vanA; 5’-
CGCAGCTTGCATGGACAA-3’ (forward), 5’-GGCGATGCCCGCATT-3’ (reverse), 5’-VIC 
-TCACTGGCCTACATTC- MGBNFQ-3’ (probe) for vanB; and 5’- 
GGAATGGCGCAAAACTTAGA -3’ (forward), 5’- AGGCCTCTCCAACTGGAACT -3’ 
(reverse), 5’-NED-TGGCGATTTCGAGTCCATTCG-BHQ1-3’-TAMRA (probe) for E. 
faecium. Reactions were performed on a 7900HT Fast Real-Time PCR System 
(Thermo Fisher Scientific, Waltham, MA, USA) in 25 µl, containing 12.5 µl ABsolute 
QPCR ROX Mix (Thermo Scientific), 5 µl template DNA, 800 nM of each primer and 
200 nM of each probe. The cycling conditions were 15 minutes at 95°C, followed 
by 42 cycles of 15 seconds at 95°C and 60 seconds at 60°C 
 
Quantification of ARGs 
For absolute quantification, control plasmids were created by cloning the 
corresponding PCR amplicons into a pGEM-T easy vector (Promega Corporation, 
Madison, WI, USA) according to the manufacturer’s protocol. Plasmids were 
isolated using standard alkaline lysis, after which these products were subjected 
to gel-electrophoresis, followed by excision of the target plasmids from the 
electrophoresis gel and purified using a GenElute™ Gel Extraction Kit (Sigma-
Aldrich). The resulting plasmids were subsequently sequenced on an ABI 3730 
DNA Analyzer (Thermo Fisher Scientific) by using the PCR primers and an ABI 
BigDye Terminator v.1.1 Cycle Sequencing Kit (Thermo Fisher Scientific). Analysis 
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of resultant amplicon sequences using BLAST (http://blast.ncbi.nlm.nih.gov/ 
Blast.cgi) confirmed identity to the respective ARGs. Concentrations of purified 
plasmids were determined using a NanoDrop 2000 UV-Vis spectrophotometer 
(Thermo Scientific) before quantitative PCR was performed on log-fold dilution 
series of the plasmid solutions to generate standard curves for quantification of 
copy numbers. 
 
Statistical analysis 
Copy numbers of ARGs within all samples were calculated by interpolation 
from the respective standard curves. To correct for the total amount of bacterial 
DNA within each sample these numbers were referred to the amount of 16S rDNA 
by dividing ARG copy numbers by that of the 16S rDNA. For one group of genes 
(cfxA, tetM and ermB) that is highly prevalent in the studied population, 
fluctuations in gene abundance were plotted on an x/y graph as ratios (figure 2). 
Values that appeared as 0 copies because of undetectable targets in the PCR 
reaction were transformed to 0.01 (origin of the axis) to allow for the use of log-
scales in this figure. This was done for 17 values in the travellers group (1 x tetM, 2 
x ermB, 14 x cfxA) and these values were excluded from subsequent statistical 
analysis. To analyse differences between our group and the travellers, copy 
numbers were log-transformed (Z=log(y/x) = log(y)-log(x)) and analysed for 
differences in mean and variance. We chose nonparametric testing because of 
failing to statistically confirm Gaussian distributions despite transformation. Two-
sided Mann-Whitney tests were performed to look for differences in distributions. 
For the less prevalent ARGs (blaCTX-M, vanA/B, qnrB and qnrS), only the prevalence 
at the different time points was calculated. 
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Results 
Study population 
Initially 25 adult healthy volunteers (14 men, 11 women) were included, of 
which 2 subjects had to be excluded because of international travel during the 4 
weeks follow-up. As such, the final study population consists of 23 subjects.  
Admission of samples by mail was chosen by seven individuals, while sixteen 
subjects delivered their samples directly to the laboratory. Five participants 
reported diarrhoea on a minimum of one questionnaire. No participant reported 
of antimicrobial- or probiotic supplement use during the study period (table 1). 
Table 1. Characteristics of both the non-travelling and travelling study populations. 
Characteristic 
Non-travellers 
(N=23) 
Travellersa 
 (N=122) 
 Median (range) 
Age (years) 31 (22-59) 43 (18-72) 
   
Sex No. (%) 
      Female 11 (47.8) 71 (58.2) 
      Male 12 (52.2) 51 (41.8) 
Diarrhea within study period  5 (21.7) 45 (36.9) 
Antimicrobial drug use 0 (0) 15 (12.3) 
Probiotic supplement use 0 (0) N.D. 
Sample Admission route    
      Mail 7 (30.4) 122 (100.0) 
      Direct 16 (69.6) 0 (0.0) 
N.D., Not determined. 
a population from a previously performed study [22]. 
 
Prevalence of ARGs in faecal samples 
Figure 1 shows the prevalence of the ARGs in faecal samples from the 23 
healthy volunteers at three consecutive time points. The cfxA, tetM and ermB 
genes were detected in all faecal samples. The ESBL encoding blaCTX-M was 
detected in two (8.7%) samples at T0, three (13%) at T1 and four (17.4%) at T3. 
The qnrB gene was detected in one (4.3%) sample at T0, none of the samples at 
T2 and again in another sample (4.3%) at T2. VanA and qnrS were undetectable in 
all samples. For the glycopeptide resistance encoding gene vanB we found 17 
(73.9%) positive samples at each time point (T0 to T2). 
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Figure 1. Prevalence (%) of ARG determinants in faecal samples from 23 healthy 
volunteers. 
 
Acquisition and loss of ARGs 
Acquisition or loss of blaCTX-M, qnrB and qnrS was detected in a few individuals. 
One individual’s faecal sample became positive for both blaCTX-M and qnrB on T2, 
while the samples were negative at T0. For another individual, the blaCTX-M gene 
was absent in T0, but detectable at T1 and T2. One individual had lost the qnrB 
gene at T1, as it was no longer detected since then. For VanB, one acquisition at 
T1 and one loss at T1 was observed. 
 
Fluctuations in gene abundance 
Changes in the abundance of the highly prevalent ARGs in the study population 
varied between a -36.55 to 9.21 (median of 1.04) fold change for cfxA, a -4.48 to 
11.38 (median of -1.14) fold change for tetM and a -10.23 to 4.94 (median of -
1.04) fold change for ermB. This is in line with earlier determined changes in the 
ARG abundance for the travelling group, median fold changes  1.00, -1.35 and  -
1.04 for cfxA, tetM and ermB respectively.   
In order to visualize the changes in ARG abundance in our study group and 
compare it to the changes in the travelling group, fluctuations from T0 to T1 and 
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T1 to T2 of the non-travelling participants were plotted as pooled ratios of ARG 
abundance (Figure 2A, C, E) and compared to the fluctuations that were observed 
in the group of travellers where the abundance before travel is plotted against the 
abundance after travel (Figure 2B, D, F). No significant differences in fluctuations 
of cfxA, tetM and ermB were seen between the two groups (p = 0.71, 0.18 and 
0.91, respectively). Fluctuations in tetM gene abundance (both increases and 
decreases) visually appeared to be larger in the travellers group (SD 1.7) 
compared to healthy volunteers (SD 11.47), however because of the non-Gaussian 
nature of the data we did not test on differences in variance with parametric 
tests. In the five samples where participants reported of diarrhoea in the past 2 
weeks, no differences in 16S rDNA load or ARG abundance was seen as compared 
to the other samples.  
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Figure 2. Absolute changes in ARG abundance. (A, C, E) Changes from T0 (x-axis) to T1 
(y-axis) pooled with changes from T1 (x-axis) to T2 (y-axis) in comparison to (B, D, F) a 
group of international travellers before (x-axis) and after travel (y-axis). Points located 
above the dashed line (---) indicate increases while points below this line represent 
decreased ARG abundances. Points that are located on one of the axis indicate acquisition 
(x-axis) and loss (y-axis) of ARGs. 
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Discussion 
With our study of short term fluctuations in the abundance of the analysed 
ARGs:  cfxA, tetM and ermB, we provide insights into the dynamics of the 
resistome of healthy adult individuals. Our findings suggest that relative changes 
in gene abundance that have previously been observed in travellers can be 
interpreted as normal fluctuations that take also place in healthy, non-travelling 
individuals. The metagenomic approach has the advantage that ARGs can be 
detected in a much wider array of species that also covers not cultivable bacteria. 
However, inherent limitations are that detected ARGs cannot be directly linked to 
specific organisms of the gut microbiota and it does not provide any information 
on functionality. The next challenge will be to determine factors that explain 
these fluctuations, such as e.g. changes in microbial composition or exposure to 
external sources of these genes.  
Our study has some limitations. First, there were some differences in the two 
compared study populations. For example, there were slight differences in the 
proportion of antibiotic use and subjects suffering from self-reported diarrhoea, 
as well as the median age between the groups. Second, the small number of 
included individuals and the consequential pooling of changes in abundance from 
T0 to T1 and T1 to T2 could have also contributed to more homologous data. The 
differences in variance of the fluctuations that were observed in tetM might be 
(partly) induced by these factors. Other possible explanations include minor 
differences in sampling methods and sample processing in the two studies as well 
as an effect of travelling on the abundance of this ARG. We also investigated the 
prevalence of the ESBL-encoding gene blaCTX-M, the quinolone resistance encoding 
genes qnrB and qnrS and the glycopeptide resistance encoding genes vanA and 
vanB at the different time points (T0-T2). Only few samples were positive for 
blaCTX-M (8 for CTX-M group 1 and 1 for CTX-M group 2), two for qnrB and none for 
qnrS or vanA. This confirms the findings in the prior study where a low prevalence 
of these genes prior to travel was observed. We found a very high prevalence of 
vanB in our group and carriage of this ARG was highly consistent over the three 
time points. Carriage of vanB was however not associated with PCR detection of 
Enterococcus spp., indicating that the genes did not originate from vancomycin 
resistant enterococci (VRE). High rates of non-enterococcal vanB carriage in fecal 
samples have previously been described [23-25]. Several non-enterococcal 
organisms of the human gut microbiota harbouring the vanB genotype have been 
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described and include species of the genus Clostridium [26, 27] and Streptococcus 
[28, 29]. Molecular characterization of this prevalent vanB genotype and 
genotypes of clinically isolated VRE as well as identification of carrying organisms 
and further transmission experiments are necessary to estimate the potential 
clinical implications that might follow an uncontrolled spread of this ARG. 
In conclusion, we showed that fluctuations in the abundance of ARGs, which 
are highly prevalent in the human gut microbiome is common and not related to 
international travel. Further investigation could determine if such fluctuations are 
brought about by changes in the microbial composition of the gut. 
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Abstract 
While antibiotic resistance is a major public health threat that we face 
worldwide, there are well recognised differences in the prevalence of resistant 
bacteria across geographic areas. Previous studies have shown that international 
travel constitutes a major factor for the spread of antibiotic resistance from 
endemic to low prevalence areas. Thus far however, no study has collected data 
on how rapid acquisitions of antimicrobial resistance genes (ARGs) or organisms 
occurs during travel. 
Stool samples from 7 consenting Dutch subjects were collected prior and after 
travelling outside of Europe. Furthermore, faecal swabs from each available day 
during travel, as well as hand-skin swabs from the first few days of travel were 
collected and immediately stored in nucleic acid stabilizing buffer. Bacterial DNA 
was directly isolated from all collected samples and subsequently screened for the 
presence of several ARGs using qPCR. 
We found that ARGs encoding for quinolone resistance (qnrB and qnrS) and for 
extended-spectrum beta-lactamases (blaCTX-M) were acquired by participants who 
had visited South-Korea, India or the Filipinas. The median time to acquisition was 
5 days, with the earliest detected ARG acquisition being on the 2nd day of travel. 
Acquired genes could in some cases be detected up to 3 months after travel.  
Our results show that the acquisition of ARG harbouring bacteria can occur 
within just several days, indicating that a relatively short exposure time to an 
environment with high rates of antibiotic resistance is sufficient to contribute to 
the spread of ARGs around the world.  
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Introduction 
The continuing global rise of antimicrobial resistance (AMR) is an increasing 
major public health threat. AMR limits clinical treatment options for bacterial 
infections, thereby reducing clinical efficacy and increasing mortality at a global 
scale. Despite the fact that AMR prevalence in the community is increasing in 
virtually all parts of the world, there are still major differences in the prevalence 
of certain antibiotic resistant bacteria between geographic areas [1]. For example, 
carriage rates of extended-spectrum beta-lactamase (ESBL) producing 
Enterobacteriaceae are much higher in Southeast Asia and the Eastern 
Mediterranean as compared to Europe and North America [2]. Similarly, 
carbapenemase producers are widespread in some areas, while they are very rare 
in other parts of the world [3, 4]. 
Previous cohort studies have shown that human travel to areas with a high 
prevalence of AMR contributes to the spread of antibiotic resistant bacteria or 
antibiotic resistance genes (ARGs) across geographic areas [5-19]. The acquisition 
of ARGs during travel may have several consequences. Firstly, exposure to or 
colonization with antibiotic resistant bacteria, such as ESBL-producing 
Enterobacteriaceae, can lead to difficult to treat infections [20-22]. Secondly, the 
import of ARGs from endemic areas to areas with a low prevalence of resistance 
could subsequently lead to further dissemination. This may occur through e.g. 
transmission to household members, but also through release of the bacteria or 
their genetic material into the environment, thereby enriching the local 
environmental resistome [23].  
Previous studies all provide evidence that acquisition of resistant bacteria 
takes place during international travel, and some risk factors for acquisition have 
been identified, no data however is available about the actual dynamics of 
changes in the resistome during travel itself. In the current study, we therefore 
aimed to investigate the dynamics of the travellers’ resistome by screening for 
several ARGs in the gut and skin microbiomes of travellers during the course of 
their travels. 
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Materials and Methods 
Study population and sample collection 
In this study, a total of 6 healthy Dutch volunteers who were planning to travel 
outside of Europe and had not used antibiotics in the previous 3 months were 
recruited. The participants were asked to collect three types of samples before, 
during and after an international trip: faecal matter, faecal swabs and hand skin 
swabs. They were also asked to provide information on the trips such as dates and 
destinations as well as any use of antibiotics during the study period.  
Faecal matter was collected before and at several time points after each trip. 
Faecal swabs were taken at the same time points as the faecal matter samples, as 
well as at each day of defecation day during travel. Hand swabs were taken from 
the palm and fingers of the dominant hand at any given point during the day, 
preferably consecutively during the first five days of travel. All swabs were 
immediately stored in DNA/RNA Shield (Zymo Research, Irvine, USA) to ensure the 
stability of the metagenome during unrefrigerated transport. 
 
Sample processing and DNA extraction 
The collected faecal samples were either immediately stored at -20°C and 
shipped to the lab under refrigerated conditions, or were stored at 4°C for one 
day and then at -20°C after being delivered to the lab the next day. The faecal and 
hand-skin swabs, suspended in DNA/RNA Shield solution as described above, 
were stored at ambient temperature during the participants’ travels and then 
either directly submitted to DNA extraction in the lab or stored at -20°C in the lab 
until DNA extraction. The sampling procedures within subjects were always the 
same. The extraction of DNA was performed as described previously [15]. Briefly, 
either 200 mg of faeces, or 200 µl of DNA/RNA Shield (in which the swabs were 
suspended) was added to a 2-mL vial containing 0.5 g of 0.1 mm zirconia/silica 
beads (BioSpec, Bartlesville, OK, USA), 4 glass beads (3.0-3.5 mm)(BioSpec) and 
1.2 ml of lysis buffer from the PSP Spin Stool Kit (Stratec Molecular, Berlin, 
Germany). Samples were disrupted in a MagNA Lyser device (Roche, Basel, 
Switzerland) in three cycles of 1 min. at a speed of 5500 rpm. Subsequently, DNA 
was isolated from the samples with the PSP Spin Stool Kit, according to the 
manufacturer’s instructions.  
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Real time PCR assays 
Real-time PCR to detect antibiotic resistance genes was performed as 
described previously for qnrA, qnrB, qnrS, blaCTX-M [15] and mcr-1 [16]. 
Amplification of carbapenemase encoding genes blaKPC, blaNDM and blaOXA-48 was 
performed in a 7900HT Fast Real-Time PCR System (Thermo Fisher Scientific, 
Waltham, MA, USA) in 25 µl volumes containing 12.5 µl ABsolute QPCR ROX Mix 
(Thermo Fisher Scientific), 5 µl template DNA, and primer/probe mix as described 
earlier [24-26]. The cycling conditions were 15’ at 95°C, followed by 45 cycles of 
15’’ at 95°C and 60’’ at 60°C. 
For blaVIM, primers  (5’-CGTGATGGYGATGAGTTGCT-3’ and 5’-
GTCATGAAAGTGCGTGGAGA-3’) and a probe (FAM-5’-
GA[+T]TGARAAGC[+A]AATTGG[+A]CT-3’-BHQ1) were designed for this study to 
cover all 51 alleles currently reported in NCBI’s GenBank, except for the divergent 
VIM-7 allele. Amplification was performed in a 7900HT Fast Real-Time PCR System 
in 25 µl volume containing 12.5 µl ABsolute QPCR ROX Mix, 5 µl template DNA, 
300 nM of both blaVIM primers and 200 nM of blaVIM probe. The cycling conditions 
were 15’ at 95°C, followed by 45 cycles of 15’’ at 95°C and 60’’ at 60°C. The 
amplification efficiency and detection limit of the blaVIM assay were determined by 
performing triplicate measurements of standard curves (series of 8 log dilutions) 
of a pGEM-T easy plasmid construct (Promega Corporation, Madison, WI, USA) 
harbouring the targeted blaVIM sequence, which was generated as described 
previously [16]. The efficiency was 98% with a detection limit of 5 gene copies per 
reaction. 
To normalize for the different amounts of bacterial DNA in the samples a 
500bp fragment 16S rDNA amplification was used.   The 16S rDNA was amplified 
on a MyiQ™ Single-Color Real-Time PCR Detection System (BioRad, Hercules, CA, 
USA) in 25 µl volume containing 12.5 µl iQ™ SYBR® Green Supermix (BioRad), 5 µl 
template DNA and 300 nM of both forward (5’- CCTACGGGNGGCWGCAG -3’) and 
reverse (5’- GACTACHVGGGTATCTAATCC -3’) primers [27]. The cycling conditions 
were as follows: 3’ at 95°C, followed by 35 cycles of 15’’ at 95°C, 20’’ at 55°C and 
30’’ at 72°C, followed by a melting curve analysis. The amplification efficiency was 
determined to be 103% by performing triplicate measurements of standard 
curves of a pGEM-T easy plasmid construct (Promega Corporation) harbouring 
targeted 16S rDNA sequence, which were generated as described previously [16].  
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Results 
In total, we investigated 7 travelling individuals, 3 female and 4 male (Trip no. 
1 and 4 were made by the same individual, see table 1) between 2013 to 2015. 
The duration of travel ranged from 10 to 21 days, with a median of 14 days. All, 
except 1 traveller who visited Canada, travels were to countries in Asia (Table 1). 
Furthermore, trips #1 and #2 were made together by companions. None of the 
participants were hospitalized and they all reported that they did not use 
antibiotics during, or in the 3 months preceding travel. 
 
Table 1: Characteristics of the study population 
Trip # Sex Age Destination Date Duration (days) 
1 M 24 South Korea 2013 12 
2 F 24 South Korea 2013 12 
3 M 37 India 2014 21 
4 M 24 India 2014 10 
5 F 38 China 2015 21 
6 F 38 Canada 2015 14 
7 M 25 Philippines 2015 14 
 
For 6 out of the 7 travels, at least one of the ARGs screened for had been 
acquired. Overall, the acquisition time of an ARGs in the gut microbiota ranged 
from 2 to 13 days, with the median being 5 days.  
Acquisition of blaCTX-M genes was detected during 2 travels (Figure 1A), with its 
earliest acquisition detected on the 8th day of the trip. For one of the travellers, 
the gene was still detectable 1 month after travel (last sampling time point for this 
traveller), whereas for the other traveller, the gene was only detectable on the 
first day after travel, but not after that. Hand skin swabs collected during trip #4 
were positive for blaCTX-M on days 2 and 6 (Figure S1A), while the faecal samples 
collected during that trip remained negative. 
While the qnrA gene was detected only once in a hand skin swab sample taken 
by the concerning traveller on the 2nd day of trip #7 (data not shown), the qnrB 
and qnrS genes were detected in 5 and 6 of the travellers respectively. Faecal 
samples of two participants already tested positive for the qnrB gene before 
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travel, whereas the gene was for the first time detected during travel in 3 other 
participants (Figure 1B). Notably, the acquisition of this gene already occurred at 
the 2nd day of travel for one participant. For one other traveller, qnrB was 
detected in his faecal microbiome only at a single day during travel, but not for 
the remainder of the trip or after the trip, suggesting only transient carriage of the 
acquired gene. For the person that made trip #3, hand skin swabs were found to 
be positive for qnrB on days 2, 3 and 20 (Figure S1B), and the gene was also 
detected in the participant’s faecal swabs from day 6 of travel onwards.  
 
 
Figure 1. Presence of (A) blaCTX-M, (B) qnrB and (C) qnrS genes in faecal metagenomes 
before, during or after international travel. Grey squares represent samples which were 
negative, while red squares represent those which were positive. Black squares represent 
time points at which no sample was collected. 1d: 1 day; 3d: 3 days; 1w: 1 week; 2w: 2 
weeks; 1m: 1 month; 3m; 3 months; 6m: 6 months. 
-  Negative sample
+  Positive sample
x  No sample available
Before
Travel # (Destination) travel 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 1d 3d 1w 2w 1m 3m 6m
1 (South Korea) - - - - - - - - - - - - - - - - - - x x
2 (South Korea) - - x - x x - x + + x + + x - - - + x x
3 (India) - - - - - - - - - - - - - + + + - x - x - + + + - - + -
4 (India) - - - - - - - - - - - - x x x x x x
5 (China) - - - - - - - - - - - - - - - - - - - - - - - - x x x x
6 (Canada) - x - - x x - x - - - - x - - - x - x x x
7 (Philippines) - - - - - - - - - - - - - - - - - - - - x x
Before
Travel # (Destination) travel 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 1d 3d 1w 2w 1m 3m 6m
1 (South Korea) - - - - - - - + - - - - - - - - - - x x
2 (South Korea) + - x - x x + x + + x + + x + + - - x x
3 (India) - - - - - - + + + - + + - + + + + x + x - + - + - + - -
4 (India) - - + + + + + + + + + + x x x x x x
5 (China) + - - + + + + + + + + + + + + + + + + + - + - - x x x x
6 (Canada) - x - - x x - x - - - - x - - - x - x x x
7 (Philippines) - - - - - - - - - - - - - - - - - - - - x x
Before
Travel # (Destination) travel 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 1d 3d 1w 2w 1m 3m 6m
1 (South Korea) - - - - - + + - - - - - - - - - - - x x
2 (South Korea) - - x - x x + x + + x + + x + + - - x x
3 (India) - - - - + - + + + + + + + + + + + x + x + + + + + + + -
4 (India) - - + - - - - - + - + + x x x x x x
5 (China) - - - - - + + + - + + - - - - - - + - - - + - - x x x x
6 (Canada) - x - - x x - x - - - - x - x - x - x x x
7 (Philippines) - - - + + + + + + + + + + + + + - - - - x x
A
B
C
During travel after travel
During travel after travel
During travel after travel
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None of the carbapenemases encoding genes blaKPC, blaNDM, blaOXA-48 and 
blaVIM, nor the plasmid mediated colistin resistance gene mcr-1 were detected in 
any of the samples.  
For several travels, some intermittently negative samples were observed. I.e., 
the traveller’s samples were positive for an ARGs for several consecutive days, 
with the exception of a few time points within that period, as is observed e.g. for 
the qnrB gene during trip #3 (Figure 1B). Analysis of the DNA load of the samples 
by determining the 16S rDNA concentration indicated that intermittent negative 
samples were in part due to a low DNA load in the samples, causing the ARG to 
drop below the detection limit, as illustrated in Figure 2.  
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Figure 2. Analysis of the DNA load in samples which were intermittently negative for an 
ARG. DNA load of the samples was determined by the PCR Ct value obtained for 16S 
rDNA. A higher Ct value represents a lower DNA load. In this example, samples which were 
intermittently negative for qnrB showed a lower DNA load in the samples, suggesting this 
may have resulted in several samples reported to be false-negative for an ARG. 
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Discussion 
The results of this study show that the acquisition of ARG harbouring bacteria 
can occur within several days. If ARG acquisition can already be detected after 
two days of travel to an endemic country, then people could be at risk during 
short visits to other places with high rates of resistance, such as hospitals and 
farms. This could have implications for individuals at higher risk of infection, such 
as persons with an impaired immune functionality. Furthermore, the observation 
that such short exposure may be sufficient for the spread of ARGs from endemic 
into a low prevalence areas highlights the importance of travel in the 
dissemination of resistance elements around the world [23].  
In all travels, except for the trip to Canada, at least one of the investigated 
ARGs was acquired. This indicates that acquisition of ARGs during travel is 
frequent. While our small study population prevents the conclusion of reliable 
prevalence data, these findings are in line with those determined in previous 
studies [28]. For example, we report the acquisition of  qnrS during 6 out of the 7 
trips. In a previous study, we showed a high acquisition rate of this ARG in 
travellers returning from Asia and Africa. Some studies from Asian countries have 
also reported a relatively high prevalence rate of qnr genes in bacterial isolates 
[29, 30] or faecal metagenomes [31]. The ESBL encoding blaCTX-M genes were 
detected in samples from participants who had visited either India or South Korea. 
Previous studies have shown that up to 88% and 67% of travellers returning from 
southern Asia and other Asian regions respectively had acquired multidrug 
resistant Enterobacteriaceae, of which the majority harboured CTX-M genes [28] 
The absence of carbapenemases encoding genes was not unexpected, as other 
travel-related cohort studies have found only sporadic acquisitions of these genes 
[19, 28]. Also, the mcr-1 gene was not detected in any sample. While acquisition 
of this gene during travel has not been reported to be as high as for example 
blaCTX-M or qnr genes, we and others have previously demonstrated the spread of 
this ARG by travellers [6, 16].  
Interestingly, blaCTX-M was detected on the hand skin swabs, but not in the 
faecal samples of one traveller who had visited India. The blaCTX-M gene is known 
to be highly endemic in India, as shown by several studies investigating e.g. 
hospitalized patients [32, 33], healthy individuals and environment [32], imported 
vegetables [34] or travellers who had visited the country [5, 9-11, 14, 18]. Thus, 
while acquisition in the gut microbiota was either not established or not detected, 
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there was exposure to this traveller in particular, and most likely also to other 
travellers in general, highlighting the potential importance of personal (hand) 
hygiene in such high risk environments in order to prevent colonisation or further 
transmission. 
In addition, for one participant, ARGs were detected during travel, but could 
not be detected at later time points of that trip or in the faecal sample collected 
upon returning home. This shows that while ARG acquisition in the gut 
microbiome may occur very rapidly, it may also be lost again before leaving the 
travel destination. As a result, a proportion of ARG acquisitions into the gut 
microbiome is not perceived when investigating only post-travel samples. Such 
short-term carriages do however pose a smaller risk, as the chance of infections 
with the resistant bacteria or onward transmission to e.g. household members or 
the home country is lower.  
The duration which resistant bacteria or ARG persist in the microbiota after 
travel has been investigated by a few studies, which show that acquired multidrug 
resistant Enterobacteriaceae persisted in 6–28% of travellers up to six months 
upon travel return [18, 28]. In the current study, the available data showed 
persistence ranging between 1 day and 3 months. More elaborate data about this, 
as well as on transmission rate to household members, is expected to be reported 
by the COMBAT study in the future [35]. 
One of the challenges in our study was the relatively low abundance of DNA 
acquired from some of the faecal swabs collected during travel, which naturally 
contained less faecal material than a stool sample collected before and after 
travel. This most likely led to the failure of detection of ARGs at certain days, while 
it was found to be present before and after that time point. Possibly, this may 
have also caused a slight underestimation of the speed of acquisition as 
determined in this study. With this in mind, future studies employing a similar 
type of sampling should be aware about collecting sufficient faecal material, 
especially considering the relatively low load of Enterobacteriaceae and their 
associated ARGs in faecal matter. 
In conclusion, in this study we have shown that acquisition of ARGs occurs very 
rapidly during travel to countries with a high prevalence of antibiotic resistance. 
Some acquisitions were detectable only during travel itself and not after return, 
demonstrating a risk which usually remains undetected. That acquisition can 
occur so rapidly also highlights the risks for visitors to other types of high risk 
environments, e.g. healthcare settings, concerning antibiotic resistance. 
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Abstract 
Background: 
Recently, the first plasmid-mediated colistin resistance gene, mcr-1, was 
reported. Colistin is increasingly used as a last resort antibiotic for the treatment 
of infections with carbapenem resistant bacteria, which have been rapidly 
disseminating worldwide in recent years. 
Objectives: 
The reported carriage rate of mcr-1 in humans remains sporadic thus far, 
except for those reported in Chinese populations. We aimed to determine its 
presence in the faecal metagenomes of healthy Dutch travellers between 2010 
and 2012. 
Methods: 
Faecal metagenomic DNA of pre- and post-travel samples from 122 healthy 
Dutch long-distance travellers was screened for the presence of mcr-1 using a 
TaqMan real-time PCR assay which was designed and validated in this study. All 
positive samples were confirmed by sequencing of the amplicons. 
Results: 
The mcr-1 gene was detected in 6 (4.9%, 95%CI 2.1-10.5) out of 122 healthy 
Dutch long-distance travellers after they had visited destinations in South(east) 
Asia or southern Africa between 2011 and 2012. One of these participant was 
already found to be positive before travel.  
Conclusions: 
Our study highlights the potential of PCR-based targeted metagenomics as an 
unbiased and sensitive method to screen for the carriage of the mcr-1 gene, and 
suggests that mcr-1 is widespread in various parts of the world. The observation 
that one participant was found to be positive before travel suggests that mcr-1 
may already have disseminated to the microbiomes of Dutch residents at a low 
prevalence, warranting a more extensive investigation of its prevalence in the 
general population and possible sources. 
 
 
Detection of mcr-1 in faecal metagenomes of Dutch travellers 
 
115 
Introduction  
The first plasmid mediated colistin resistance gene, mcr-1, was recently 
reported by Liu and colleagues [1]. Before their findings, colistin resistance was 
considered to arise due to chromosomal mutations [2], and therefore believed to 
have a limited dissemination, restricted to clonal transmission. Colistin is 
increasingly used as a last resort antibiotic for the treatment of infections with 
carbapenem resistant bacteria, which have been rapidly disseminating worldwide 
in recent years [3]. Thus, the finding of plasmid-mediated colistin resistance has 
rightfully drawn renewed attention to colistin resistance. Considering the 
successful dissemination of genes encoding extended-spectrum beta-lactamases 
(ESBLs), carbapenemases and other resistance mechanisms by horizontal gene 
transfer [4], the mobile colistin resistance gene mcr-1, which could facilitate a 
similar successful dissemination for resistance to colistin, may have major 
implications for public health. 
Liu et al. described a high prevalence of mcr-1 in E. coli isolates from retail 
meat (15%), pigs at slaughter (21%) and a relatively lower prevalence in E. coli and 
K. pneumoniae isolates from human patients (1.4% and 0.7% respectively), raising 
the concern whether this gene had spread outside of China [1]. Shortly after their 
report, several other studies have investigated and confirmed the occurrence of 
mcr-1 in various parts of the world, including several parts of Asia [5-10], as well 
as Europe [11-22] and Africa [23, 24]. 
While the rates of mcr-1 positive strains isolated from animals or food was 
quite high according to some of these studies [5, 24], the reported carriage rate in 
humans thus far remains sporadic except for those reported in Chinese 
populations [25]. 
The studies performed thus far have focused on either detecting mcr-1 in 
existing collections of cultured isolates, or by mining metagenomic sequencing 
data.  As these existing collections were mostly restricted to specific 
microorganisms, resistance profiles (e.g. ESBLs) or patient populations, and 
sensitivity of sequence-based metagenomics is relatively low, we hypothesized 
that the prevalence of mcr-1 as reported in these studies might be an 
underestimation of the human carriage rates in the community.  
In the current study, we applied a PCR-based targeted metagenomic approach 
to screen for the presence of the mcr-1 gene in the faecal metagenomes of 
healthy Dutch travellers between 2010 and 2012. In addition, from faecal samples 
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screened positive for the presence of the mcr-1 gene by this method,  isolates 
harbouring the mcr-1 genes were cultured in order to define the characteristics of 
those strains. 
 
Methods 
Study population 
This study comprised 122 healthy Dutch long-distance travellers, who had 
been recruited in a prospective travel cohort study as described previously [26]. 
Shortly, participants were recruited between November 2010 and August 2012 
through travel clinics (EASE Travel Clinic & Health Support, www.ease-
travelclinic.nl/en/) located in the southern part of the Netherlands. Consenting 
participants were asked to collect a faecal sample before and  on average 1 week 
after travel, along with records of the duration and destination of their travel, 
illnesses or complaints during travel and antimicrobial drug use within the 3 
months preceding post-travel sampling. 
 
Faecal processing and metagenomic DNA extraction 
Processing and DNA extraction of faecal samples was described previously 
[26]. In brief, faecal samples were 10-fold diluted in peptone/water (Oxoid, 
Basingstoke, United Kingdom) containing 20% (vol/vol) glycerol (Merck, 
Darmstadt, Germany), homogenized by vortexing and stored at −20°C until further 
analysis. For the extraction of metagenomic DNA, 200 µl of diluted faeces was 
added to a 2-mL vial containing 0.5 g of 0.1 mm zirconia/silica beads (BioSpec, 
Bartlesville, OK, USA), 4 glass beads (3.0-3.5 mm)(BioSpec) and 1.2 ml of lysis 
buffer from the PSP Spin Stool Kit (Stratec Molecular, Berlin, Germany). Samples 
were disrupted in a Magna Lyser device (Roche, Basel, Switzerland) in three cycles 
of 1 min. at a speed of 5500 rpm. Subsequently, metagenomic DNA was isolated 
from the samples with the PSP Spin Stool Kit, according to the manufacturer’s 
instructions.  
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Molecular detection of antibiotic resistance genes 
In order to obtain increased assay specificity on metagenomic samples, a 
TaqMan qPCR assay was developed and validated in this study. In addition to 
using the primers described by Liu et al [1] (forward: 5’-CGGTCAGTCCGTTTGTTC-
3’, reverse: 5’-CTTGGTCGGTCTGTAGGG-3’), IDT’s PrimerQuest Tool (idtdna.com) 
was used to design a probe (5’-TTGACCGCGACCGCCAATCTTA-3’) which was 
labelled with a FAM reporter and a Black Hole Quencher (BHQ1) (Sigma-Aldrich, 
St. Louis, MO, USA). Amplifications were performed on a 7900HT Fast Real-Time 
PCR System (Thermo Fisher Scientific, Waltham, MA, USA) in 25 µl reactions 
containing 12.5 µl ABsolute QPCR ROX Mix (Thermo Fisher Scientific), 5 µl 
template DNA, 300 nM of both the forward and reverse primer and 200 nM of 
probe. Thermal cycling consisted of 15 minutes at 95°C, followed by 45 cycles of 
15 seconds at 95°C and 1 minute at 60°C. In order to assess efficiency of the assay, 
a control plasmid was created by cloning the corresponding PCR amplicon into a 
pGEM-T easy vector (Promega Corporation, Madison, WI, USA) according to the 
manufacturer’s protocol. Plasmids were isolated using standard alkaline lysis, 
after which these products were subjected to gel-electrophoresis, followed by 
excision of the target plasmids from the electrophoresis gel and purified using a 
GenElute™ Gel Extraction Kit (Sigma-Aldrich). Finally, quantification was 
performed with a Quant-iT™ PicoGreen® dsDNA Assay Kit (Thermo Fisher 
Scientific). Standard curves were then generated by triplicate measurements of 
serial dilutions of the control plasmid, as well as triplicate measurements of serial 
dilutions of the control plasmid spiked into 3 different (faecal) metagenomic DNA 
samples. 
All samples indicated as positive by qPCR were confirmed by sequencing using 
the PCR primers and a BigDye Terminator v1.1 Cycle Sequencing Kit (Thermo 
Fisher Scientific). Sequencing data were obtained on an ABI 3730 DNA Analyzer 
(Thermo Fisher Scientific) and were analysed by using NCBI’s Basic Local 
Alignment Search Tool (BLAST). Real-time PCR to detect blaCTX-M, qnrA, qnrB and 
qnrS genes in mcr-1 harbouring isolates obtained in this study was performed as 
described previously [26]. 
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Microbiological methods 
Faecal samples (diluted as described above), which tested positive for the mcr-
1 gene were streaked onto lysogenic broth (LB) agar plates containing colistin (2 
mg/L) and vancomycin (50 mg/L) and incubated overnight at 37°C in order to 
obtain colistin resistant isolates. Resulting colonies were visually inspected and 
Gram-negative suspected colonies were subsequently cultured onto new LB agar 
plates containing colistin and vancomycin. Once the cultures were visually 
confirmed to be pure and resistant to colistin, they were streaked onto blood agar 
plates (Becton-Dickinson, Franklin Lakes, NJ, USA) for identification by MALDI-TOF 
(bioMérieux, Marcy l’Etoile, France) and antibiotic susceptibility testing (AST) 
using the BD Phoenix Automated Microbiology System (Becton-Dickinson) and 
Etest for colistin (bioMérieux); results were interpreted according to the European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) [27]. Additionally, 1 
colony was suspended into 500 µl of sterile ddH2O, lysed by heating to 95°C for 10 
minutes and centrifuged at 16,000g for 1 minute. The resulting supernatants were 
used for molecular confirmation of resistance genes. 
Faecal samples which did not yield colistin resistant bacteria with the above 
described approach were enriched by culturing in brain heart infusion (BHI) broth 
supplemented with vancomycin (50 mg/L) and incubated overnight at 37°C while 
shaking. Subsequently, these cultures were streaked onto BHI agar plates 
containing colistin (2 mg/L) and vancomycin (50 mg/L), followed by selection of 
suspected colistin resistant, Gram-negative colonies as described above. 
 
Molecular typing 
PFGE was performed on colistin resistant E. coli isolates essentially according 
to the rapid procedure described previously [28]. After 15 minutes of pre-
incubation in 200 µl of the restriction enzyme buffer, supplemented with 100 
µg/ml BSA, ~2x5 mm thick slices of each plug were incubated at 37°C for 3 h with 
30 Units of XbaI enzyme in 100 µl of the restriction enzyme buffer + 100 µg/ml 
BSA. Fragments were separated on a 1% SeaKem Gold agarose gel for 16 h. 
Salmonella serotype Braenderup H9812 strain (ATCC strain BAA-664) was included 
as reference strain. The resulting gel was analysed with BioNumerics v7.5 and  
according to the Tenover criteria [29]. MLST was performed according to Wirth et 
al [30]. 
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Results 
Validation of a TaqMan qPCR assay for metagenomic screening 
We developed a 309 bp real-time PCR assay using a Taqman probe. The 
primers and probe were matched against all mcr-1 entries in GenBank. At this 
time however, no variations in nucleotide sequences have been documented. In 
order to assess the specificity of the designed assay, all metagenomic DNA 
isolations of faecal samples (122 pre- and 122 post-travel) were analysed, 
resulting in 0 false positive signals. The assay was linear over 8 log dilutions of a 
control plasmid (Ct-value range: 10.7-33.5, max. variation between replicates 0.42 
Ct, slope: -3.378, R2: 0.999), with an efficiency of 98% (Figure 1). While 
concentrations of ~5 plasmid copies per reaction were no longer within the linear 
reach and showed greater variation between replicates (Ct-value 36.4-37.7), they 
were nonetheless reproducibly detectable. Measuring log dilutions of the control 
plasmid spiked into DNA isolated from faecal samples yielded a similar efficiency 
(slope = -3.341, R2 = 0.999) and sensitivity (data not shown). 
 
 
Figure 1: Standard curve of the mcr-1 TaqMan qPCR assay. Generated using serial (10-
fold) dilutions of recombinant plasmid DNA containing the targeted mcr-1 sequence. The 
average plus error bars (SD) of triplicate measurements of Ct values for each dilution are 
plotted against the number of plasmid copies per reaction. The slope of the standard 
curve was -3.378 with an R
2
 of 0.999. 
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High prevalence of mcr-1 in human faecal metagenomes 
Screening of the faecal metagenomes of 122 travellers before and after travel, 
yielded 7 samples positive for mcr-1 in total according to qPCR (Ct-value range: 
24.1-40.2). Positive samples were all confirmed by sequencing, showing high 
specificity of the PCR assay (no false-positives were observed). For one 
participant, the mcr-1 gene was detected in both the pre- and post-travel sample, 
whereas for 5 other participants only the post-travel sample was found to be 
positive, reflecting a post-travel prevalence of 4.9% (95% CI 0.021-0.105) and 
acquisition rate of 4.1% (95% CI 0.015-0.096). Travellers with suggested mcr-1 
acquisition visited destinations in South(east) Asia or southern Africa, specified in 
more detail in Table 1. Half of the participants who were positive for mcr-1 after 
travel had used antibiotics in the three months preceding post-travel sampling 
(Table 1), as compared to 9.5% of non-positive participants (p<0.05).   
 
Table 1: Characteristics of participants positive for mcr-1 carriage and antibiotic resistance genes (ARGs) detected in 
faecal metagenomes of 122 Dutch international travellers. 
Participant 
Nr. 
Age Sex Travel 
duration 
(days) 
AB 3 months 
preceding 
post-travel 
sampling 
Destination Date of 
return 
ARGs in faecal 
metagenome  
pre-travel 
ARGs in faecal 
metagenome 
post-travel 
1 55 M 5 Minocycline Thailand May 
2011 
- mcr-1, qnrS 
2 69 M 21 - Vietnam March 
2011 
qnrB mcr-1, CTX-
M-2a, CTX-M-
9a, qnrA, 
qnrB, qnrS 
3 24 F 18 - Indonesia June 
2011 
- mcr-1, qnrS 
4 26 F 21 - Tanzania June 
2011 
- mcr-1, qnrS 
5 40 F 35 Trimethoprim
-
sulfamethoxa
zole 
Thailand & 
Vietnam 
Januari 
2012 
- mcr-1, qnrB, 
qnrS 
6 46 F 10 Azithromycin India May 
2012 
mcr-1, qnrB mcr-1, qnrB, 
qnrS 
AB, Antibiotic. 
aCTX-M phylogenetic group as determined by qPCR. 
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Characteristics of the mcr-1 harbouring strains 
The 7 faecal samples of participants which tested positive for mcr-1 with the 
targeted metagenomic approach were cultured in order to obtain colistin 
resistant Gram-negative bacteria. Three mcr-1 harbouring, colistin resistant E. coli 
isolates were obtained, which are specified in Table 2. Although 2 of these isolates 
were obtained from participant #6 (one before travel; isolate 6T0, and one after 
travel; isolate 6T1), these strains were distinct as determined by PFGE (Figure 2) 
and MLST (Table 2) and moreover showed different AST profiles (Table 2). 
Considering the acquisition of other resistance genes in the faecal microbiomes 
mentioned in Table 1, the isolated mcr-1 positive strains were also tested for the 
presence of blaCTX-M, qnrA, qnrB and qnrS genes, but were negative. 
 
Table 2: MLST and antibiotic susceptibility testing profiles of mcr-1 harbouring E. coli isolated from Dutch 
human faecal samples. 
Isolate ID: 2T1 6T0 6T1 
MLST: ST 1011 ST 744 ST 80 
 MIC(mg/L) (S/R)a MIC(mg/L) (S/R) MIC(mg/L) (S/R) 
Amikacin <=4 (S) <=3 (S) <=4 (S) 
Amoxicillin-Clavulanate 32/2 (R) 4/2 (S) 4/2 (S) 
Ampicillin >8 (R) >8 (R) <=2 (S) 
Cefepime <=1 (S) <=1 (S) <=1 (S) 
Cefoxitin <=4 (S) <=4 (S) <=4 (S) 
Ceftazidime <=1 (S) <=1 (S) <=1 (S) 
Ceftriaxone <=1 (S) <=1 (S) <=1 (S) 
Cefuroxime 4 (S) 4 (S) <=2 (S) 
Ciprofloxacin >1 (R) >1 (R) <=0.25 (S) 
Colistinb 3 (R) 3 (R) 3 (R) 
Ertapenem <=0.25 (S) <=0.25 (S) <=0.25 (S) 
Gentamicin <=1 (S) <=1 (S) <=1 (S) 
Imipenem <=0.25 (S) <=0.25 (S) <=0.25 (S) 
Levofloxacin >2 (R) >2 (R) <=0.5 (S) 
Meropenem <=0.125 (S) <=0.125 (S) <=0.25 (S) 
Piperacillin >16 (R) >16 (R) <=4 (S) 
Piperacillin-Tazobactam <=4/4 (S) <=4/4 (S) <=4/4 (S) 
Temocillin 16 (-) <=4 (-) <=4 (-) 
Tigecycline <=0.5 (S) <=0.5 (S) <=0.5 (S) 
Tobramycin 2 (S) <=1 (S) <=1 (S) 
Trimethoprim-Sulfamethoxazole >4/76 (R) >4/76 (R) <=1/19 (S) 
MIC, Minimal Inhibitory Concentration; (R), resistant; (S), susceptible; (-), no breakpoint available. MICs above the 
breakpoint (R) are indicated in bold.  
aInterpretation according to EUCAST clinical breakpoints. 
bAs determined by Etest. 
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Figure 2: Pulsed-field gel electrophoresis of the three mcr-1 harbouring E. coli 
isolated from Dutch human faecal samples. Genomes of all three strains, restricted with 
XbaI, have a clear distinct PFGE band-pattern, showing that the two isolates acquired from 
the pre- (isolate 6T0) and post-travel (isolate 6T1) faecal sample of the same participant 
are both unique strains.   
 
Discussion 
The first plasmid-mediated colistin resistance gene, mcr-1, has only recently 
been described. As such, information on the extent to which this gene has 
disseminated globally is still limited. Thus far, the reported carriage rate in 
humans in Europe remains sporadic [25]. In our study, we report the occurrence 
of mcr-1 in the faecal microbiota of Dutch international travellers using a 
targeted, PCR-based metagenomic approach. Bontron et al. previously described 
a SYBR Green-based real-time PCR to overcome false-positive signals, which were 
observed with earlier published primers [31]. However, since metagenomic DNA 
samples are more prone to induce unspecific amplification due to the diversity of 
DNA templates present compared to e.g. DNA isolated from bacterial isolates, we 
opted for the addition of a TaqMan probe in our assay. The designed TaqMan 
assay was shown to be both specific and sensitive when used on isolated as well 
as on metagenomic samples. 
Bacteria harbouring mcr-1 could be cultured from some, but not all 
investigated faecal samples that tested positive for this gene by qPCR. Likely, the 
(viable) bacterial load in the samples was too low or negatively affected by 
storage, as there was also an absence of growth of any other colistin resistant 
Gram-negative bacteria. Alternatively, the mcr-1 genes could be non-functional, 
non-expressed or originate from organisms not readily cultivatable with the 
currently used methods. 
This study therefore shows a relatively high post-travel prevalence (4.9%) of 
mcr-1 in the microbiota of travellers. The pre-travel prevalence (0.8%) was much 
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lower indicating that the mcr-1 carriage rate in the general Dutch population is 
low, which is in line with the recently reported absence of mcr-1 in a large 
collection (2275 isolates) of ESBL-producing Enterobacteriaceae from hospitalised 
patients, clinical cultures and outbreaks in healthcare settings in The Netherlands 
[32]. However, the high acquisition rate suggests that this mobile gene has 
already disseminated at high rates in certain parts of the world, and travel to such 
high-risk areas is a risk factor for its acquisition and further dissemination. 
With regards to this, Arcilla and colleagues previously reported that 6 (<1%) 
out of 633 ESBL-producing Enterobacteriaceae which were acquired by Dutch 
international travellers were positive for mcr-1 [33]. In our study, we did not 
select for travel-associated ESBL-producing isolates, but rather screened all faecal 
metagenomes, which most likely accounts for the higher acquisition rate. As such, 
it would be interesting to also apply a targeted metagenomic approach to study 
populations of such a magnitude.  
Many studies on mcr-1 have investigated collections of ESBL producing 
Enterobacteriaceae, and it has been reported that mcr-1 positive isolates often 
carry multiple resistance genes, including genes encoding for ESBLs [25]. For this 
reason, we investigated the antibiotic resistance profiles of the three isolates 
obtained from our study population. These were all determined to be non-ESBL-
producers however. Notably, one isolate (6T1) was susceptible to all tested 
antibiotics other than colistin. To this end, there is a need for studies without 
selections based on resistance profiles to more clearly define this relationship.  
While mcr-1 was detected in an E. coli isolate from chicken in China dating 
back to the 1980s [34], its earliest known occurrence in human samples was 
reported to be from somewhere before 2010 in China [25], and from 2011 in 
Europe (The Netherlands) [35]. Arcilla et al. previously reported that Dutch 
international travellers had acquired mcr-1 positive ESBL strains between 2012 or 
2013 [33], demonstrating the dissemination of mcr-1 by travel. The results in our 
study confirm those findings. Antibiotic use in the three months prior to post-
travel sample collection was found to be a risk factor in our study. This is in line 
with previous reports that identified antibiotic use as a risk factor for the 
acquisition of ESBL-producing Enterobacteriaceae during travel [36]. Additionally, 
we report that one Dutch citizen carried an mcr-1 positive isolate (6T0) early in 
2012, prior to traveling. This indicates that mcr-1 may already be established in 
the microbiomes of Dutch residents at a low prevalence since that time and 
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possibly earlier. We can however not rule out that carriage was due to recent 
travel, since travel history prior to enrolment in this study was unknown. 
In conclusion, we report a relatively high mcr-1 prevalence in microbiomes of 
Dutch residents after international travel, highlighting the potential of PCR-based 
targeted metagenomics as an unbiased and sensitive method to screen for the 
carriage of mcr-1. The high acquisition rates show that travel contributes to the 
dissemination of mcr-1. Isolates obtained in this study were all non-ESBL-
producers and one was even susceptible to all antibiotics except colistin. This 
suggest that it would be of interest for further studies into the occurrence of mcr-
1 to not only investigate bacterial isolates with specific resistance profiles. 
Furthermore, that one participant was positive for mcr-1 before travel indicates 
that the gene may already be present in the microbiomes of Dutch residents at a 
low prevalence, warranting a more extensive investigation of its prevalence in the 
general population and possible sources. 
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The role of the resistome & antibiotic resistance in patient care 
The emergence and spread of antibiotic resistance among pathogenic bacteria 
is a growing threat for public health worldwide. With increasing resistance against 
even the last resort antibiotics, this problem is now reaching a level where an 
increasing number of infections are extremely difficult to treat or may even 
become completely untreatable [1, 2]. In chapter 2, we underscore the 
importance of that not only antibiotic resistance in clinically relevant pathogens is 
of importance. In various environments, bacteria live in complex communities, 
where they are able to exchange genes via horizontal gene transfer (HGT). Thus, 
these communities can act as reservoirs of resistance, in which antibiotic 
resistance genes (ARGs) in one species can be transferred to other, potentially 
pathogenic, bacteria. 
The significance of such reservoirs with regard to the resistance that is 
encountered in the clinic has been demonstrated by several gene transfer events. 
Perhaps the most important example is the one concerning the blaCTX-M genes, 
currently the most prevalent extended-spectrum β-lactamases (ESBLs) encoding 
genes in Enterobacteriaceae worldwide [3], which originate from various 
environmental Kluyvera species [4]. Several other gene transfer events from 
commensals or even waterborne environmental bacteria into human pathogens 
have been described [5-8], and many other clinically relevant ARGs are believed to 
have originated from non-pathogenic bacteria. 
Because of such interactions both within and between these different 
communities, the effects of antibiotic selection pressure on not only pathogens, 
but all microbes in our gut, other animals, and the environment should be taken 
into account. An increase of resistome elements within these microbial 
ecosystems, even if not directly in human pathogens, may eventually reach into 
the clinic and have major consequences for public health. 
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The human gut resistome  
As any other microbial community, the human gut microbiome harbours 
numerous antibiotic resistance genes (Ch 4A, 4B, [9-14]). With the potential of 
HGT within these resistance reservoirs in mind (Ch 2), the human gut microbiota 
warrants special attention, due to its high density of microorganisms [11, 13]. The 
gastrointestinal tract is constantly exposed to numerous bacteria from the 
environment, via e.g. food, water, soil and other humans or animals. These 
incoming bacteria often harbour antibiotic resistance genes [15], which may be 
transferred to the indigenous microbial communities, enriching the pool of 
available AMR elements in the gut microbiota. While some studies have shown 
that ARGs are present within the gut microbiota from early life and without any 
previous antibiotic exposure [16-18], data on how the gut resistome develops and 
how it is influenced by external factors is limited. Changes to the developing 
microbiota may however permanently alter both its composition as well as its 
associated resistome. 
In chapter 3 we showed that already within a few weeks after birth, several 
ARGs can be detected in the gut microbiota of infants. At later time points, the 
prevalence of most genes increased, suggesting that they slowly accumulate as 
the microbiota develops. The aminoglycoside resistance encoding gene aac(6’)-
aph(2”) became less prevalent over time however, indicating that some ARGs are 
lost or become less abundant. During infancy and early childhood, the microbial 
composition fluctuates rapidly and is influenced by many different factors, such as 
the mode of delivery, type of infant feeding, gestational age and antibiotic use 
[19, 20]. In part, we were able to show that the observed fluctuations in ARGs 
were correlated to fluctuations in certain groups of bacteria (e.g. a higher 
abundance of bacteroides), and concluded that the composition of the resistome 
at this age is largely shaped by the shifts in the bacterial community structure of 
the gut. Likely related to this finding, we showed that factors such as the mode of 
birth and the duration of breastfeeding, not only affected the gastrointestinal 
microbial composition but also the prevalence of several ARGs. While our results 
provide a representation of microbial composition changes by looking at several 
main bacterial groups, a more detailed correlation between changes in ARGs and 
microbial composition by performing 16S rDNA sequencing could provide further 
insights. In their study on the gut resistome development of twins, Moore et al. 
showed  that environmental factors early in life shape resistome development 
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and, in agreement with our study, concluded that infants’ gut resistomes are likely 
a reflection of community composition [21]. Together with our results, this 
indicates that early exposure to organisms harbouring resistance determinants 
which may be shared with opportunistic pathogens could lead to their 
establishment in resistome and pose a risk for future infections. 
 
Travel and the spread of antibiotic resistance 
In an era of increasing globalization, the acquisition and dissemination of 
antibiotic resistant bacteria through international travel is a major concern. While 
exposure to antibiotic resistant bacteria during a travel is a risk for developing 
infections with such resistant bacteria, the geographic transfer of resistome 
elements could also lead to their introduction and further dissemination in other 
environments. 
In chapter 4A we investigated the effect of international travel on the gut 
resistome in a prospective cohort study. The results of this study show that genes 
encoding ESBLs (blaCTX-M) were acquired at high rates in travellers who visited Asia 
of Africa. Especially travellers who visited the Indian subcontinent were at high 
risk for acquiring blaCTX-M (>58%). Previous studies investigating the acquisition of 
ESBL-producing Enterobacteriaceae in travellers have also shown high acquisition 
rates (up to 88%) for destinations in Southern Asia [22]. This indicates that travel 
to these area’s is an important factor contributing to the dissemination of ARGs 
from endemic to low prevalence areas. Due to our metagenomic approach, we 
were able to demonstrate that other ARGs were acquired during travel as well. 
This became apparent from the finding that the plasmid mediated quinolone 
resistance genes (qnrB and qnrS) were also acquired at high rates. For qnrS, the 
risk was the greatest for travellers who visited Asia, and especially those that 
visited Cambodia, Thailand or Vietnam (>81% acquisition). The latter country has 
previously shown to be highly endemic for qnr genes [23]. While our study 
focused on a selection of ARGs, these findings highlights the high probability of 
many other ARGs, which are endemic in certain areas, being introduced to low 
prevalence areas by travellers. With regard to this, there is likely an import of 
carbapenemase genes from high prevalence countries in the Mediterranean area 
such as Italy [24], Turkey and Greece [25, 26]. Travellers to these area’s generally 
do not visit travel clinics and actual data, while relevant, are therefore 
unfortunately very limited. A follow-up on this particular study population was not 
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performed, and thus it is unknown for how long the acquired ARGs remained in 
the gut microbiome. While some studies have investigated the persistence of 
acquired ESBL producers using culture based methods [27-30], additional efforts 
from metagenomic studies will provide insights on the dynamics and fate of 
acquired ARGs.  
In chapter 4A we described the observation that in adults  some ARGs were 
already highly prevalent before international travel and fluctuated in their 
abundance. This could be putatively attributed to effects of traveling. In chapter 
4B we showed however that in non-travelling adults, similar fluctuations were 
observed for these specific ARGs and therefore likely represent normal short term 
changes in the commensal microbiota. Changes in microbial composition during 
international travel have thus far not been investigated, but may be correlated 
with acquisitions of specific ARGs. For example, individuals with a decreased 
colonization resistance may be more prone to microbial composition changes, 
including increases of Enterobacteriaceae and their associated ARGs. 
While we [31, 32] and others [22, 33-35] have shown that acquisition of ARGs 
and antibiotic resistant bacteria takes place during international travel, no data 
were available on how rapid ARG acquisition may actually take place. This 
prompted us to focus on the dynamics of the resistome during the actual travel in 
chapter 5. By collecting consecutive samples before, during as well as after travel, 
we were able to show that acquisition of ARGs can take place within days. The 
median time to acquisition was 5 days, indicating that acquisition occurs rapidly 
and even short visits to endemic areas are sufficient to contribute to the 
dissemination of antibiotic resistance. This also highlights the possible 
implications for short visits to other types of high-risk environments, such as 
hospitals or farms. While it only takes a short time for acquisition to take place, its 
effects may be long lasting. In our limited population size, ARGs were in some 
cases detectable up to 3 months after travel. Other studies have shown that 
resistant organisms acquired during travel persisted up to 6 months in 6-24% of 
the travellers [27-30]. As long as carriage persists, there is an increased risk for 
infections with such resistant bacteria [36], as well as for further dissemination to 
e.g. household members [37]. Moreover, there is a constant exposure of the 
environment through excretion of resistant bacteria or ARGs (Ch 2). 
The first plasmid-mediated colistin resistance gene, mcr-1, has only recently 
been described. The dissemination of this gene may have major consequences, as 
it can render multidrug resistant bacteria unsusceptible to even the last available 
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treatment option. Information on the extent to which this gene has disseminated 
globally is still limited. While the rates of mcr-1 positive strains isolated from 
animals or food in certain regions was quite high according to some studies [38, 
39], the reported carriage rate in humans in Europe thus far remains sporadic 
[40]. In chapter 6 we investigated whether travellers were being exposed to this 
gene, thereby possibly contributing to its dissemination. In a PCR, metagenome 
samples are more prone to induce unspecific amplification due to the high 
diversity of DNA templates present compared to e.g. DNA isolated from bacterial 
isolates. Moreover, the assay described by Liu et al [41] was previously shown to 
generate false-positives on bacterial isolates [42]. To be able to reliably 
investigate the (faecal) metagenome for mcr-1, we therefore developed a new 
real time PCR. With this sensitive and specific PCR assay, we found that for one 
participant, the mcr-1 gene was detected in both the pre- and post-travel sample, 
whereas for 5 other participants only the post-travel sample was found to be 
positive. This suggests that this gene is already present at high rates in certain 
parts of the world, and confirms that travel to such high-risk areas is a risk factor 
for its acquisition and further dissemination.  
 Bacterial isolates harbouring the mcr-1 gene could not be isolates from all 
faecal samples in which the gene was detected. While it is likely that this is due to 
decreased bacteria viability in those samples, it would be interesting to determine 
the location of the detected genes, as they could also be present in non-readily 
cultivable bacteria. As such, additional studies are required to more extensively 
determine the role of travel in the dissemination of mcr-1. Due to its recent 
discovery and possible implications for antibiotic therapy, a great amount of 
research from various parts of the world is being performed on mcr-1 [40, 43]. 
The results of these and future studies will provide much more needed insights 
into its prevalence and importance in humans, animals and the environment. 
From this, we may assess the gravity of the mcr-1 situation and act accordingly. A 
number of findings indicate that mcr-1 may be of animal-associated bacterial 
origin [44], which prompts for heavy restriction or even a ban of polymyxin usage 
in agriculture. 
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Concluding remarks and future perspectives 
Considering the emergence of antibiotic resistance since the use of antibiotics 
by humans, it is clear that efforts must be made to prevent its further 
dissemination. If we wish to maintain the therapeutic use of current antibiotics, 
and perhaps even more importantly: those which may be discovered or 
synthesized in the future, certain measures must be undertaken globally. Some 
major issues which would need to be addressed are for example: (I) the massive 
exposure of the environment to antibiotic waste; (II) the mass use of antibiotics as 
growth promotors and prophylactic medicine in agriculture, and; (III) the non-
prescribed and inadequate use of antibiotics for human medicine.  
Efforts to better regulate those issues are being made in certain parts of the 
world; as for example antibiotic stewardship is increasingly employed in 
healthcare facilities [45]. Also, in several northern European countries major 
improvements in agricultural use of antibiotics have been achieved [46, 47]. The 
effects of such regulations will remain largely limited to specific area’s or 
countries however, as in other parts of the world, extreme opposites such as 
completely unregulated ‘over the counter’ sale of antibiotics is still common 
practice [48-50], regulations for agricultural use of antibiotics are lacking [51] and 
uncontrolled exposure of the environment to antibiotics is dramatic [52]. 
Despite the fact that a lack of such regulations may be regional, it will continue 
to drive a global increase in the prevalence of antibiotic resistant bacteria through 
e.g. trade and travel networks. Therefore, there is still a need to more clearly 
define the impact of travelling on the dissemination of antibiotic resistance. 
Future studies need to further clarify how long acquisition of ARGs or resistant 
bacteria is maintained, what risk this poses, and whether further dissemination to 
e.g. household members or the environment takes place. Additionally, the 
acquisition of carbapenemase-encoding genes from travel to endemic countries, 
as well as that of mcr-1 is still understudied and will be a valuable point of focus. 
Since carbapenems and polymyxins will be increasingly required as treatment 
options, it is pivotal to better identify dissemination routes of genes encoding 
resistance to these last-resort antibiotics. Unravelling human-to-human or 
environmental dissemination routes might provide new leads to enforce 
additional (hygiene) precautions e.g. in  case of hospital admittance of patients 
who recently travelled to endemic areas. There is also a need to more clearly 
define the consequences of the dissemination of ARGs by human activities in 
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general. It is for example poorly understood how the introduction of (organisms 
harbouring) ARGs into an environment affect its resistome. This includes the initial 
acquisition of ARGs into the gut resistome of humans or animals, but also their 
subsequent dissemination into e.g. the direct environment of the microbe’s host, 
or to wastewaters, and so on. Eventually, it will be essential to investigate to what 
degree such effects are linked to antibiotic resistance encountered in the clinic. 
Currently, the breach in the last line of available antibiotics for multidrug 
resistance by the discovery of mcr-1 and mcr-2 [53] has emphasized that novel 
antibiotics are desperately required. Just as largely unexplored bacterial 
ecosystems contain numerous ARGs, they are most likely also an untapped source 
of novel antibiotics. Similar to how teixobactin was recently discovered [54], novel 
ways to cultivate microorganisms from ecosystems such as the soil or marine 
environment [55, 56] may therefore lead to the discovery of new antibiotics. Strict 
regulations, as discussed earlier, for the use of any of such novel antibiotics will be 
required however. If such regulations are not upheld, there is no reason their 
therapeutic use will not meet the same fate as that of the current antibiotics. 
Most likely, resistance against such novel antibiotics will emerge from the same 
ecosystems from which they were discovered, and the use of metagenomics could 
identify and monitor such resistance before it emerges in human pathogens, if not 
already present there. Similarly, by performing functional metagenomic studies, 
novel genes encoding resistance against the current antibiotics will be identified. 
This will improve the annotation power of sequence based studies and will allow 
for more information to be extracted from the sequencing of bacterial 
communities, as well as from already existing sequence data. Also, the 
identification of unknown ARGs will allow for targeted metagenomic approaches 
to interrogate such communities for the presence and abundance of those genes. 
Thus, by employing a combination of these different metagenomic techniques, 
the presence and spread of antibiotic resistance not only in human pathogens, 
but in all bacterial ecosystems which serve as a potential reservoir of resistance 
can be further unravelled. Such efforts will be required in order to take 
appropriate measures to limit the dissemination of resistance against both the 
current, and any novel antibiotics. 
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De rol van het resistoom & antibioticaresistentie in de 
patiëntenzorg 
De opkomst en verspreiding van antibioticaresistentie onder pathogene 
bacteriën is wereldwijd een toenemend probleem voor de volksgezondheid. Door 
toenemende resistentie tegen zelfs de laatste redmiddelen onder de antibiotica, 
bereikt dit probleem nu een punt waarop een toenemend aantal infecties erg 
moeilijk, of zelfs onmogelijk te behandelen zijn. In hoofdstuk 2 benadrukken we 
het belangrijke feit dat niet enkel antibioticaresistentie zoals die voorkomt in 
klinisch relevante pathogenen van belang is. In diverse omgevingen leven 
bacteriën in complexe gemeenschappen, waar zij genen met elkaar kunnen 
uitwisselen door middel van horizontale gen overdracht. Derhalve fungeren deze 
gemeenschappen als reservoirs van resistentie, waar antibioticaresistentie genen 
(ARGs)  van de ene bacteriesoort kunnen worden overgedragen naar andere, 
mogelijk pathogene, bacteriën. 
Het belang van zulke reservoirs met betrekking tot de resistentie die in de 
kliniek wordt aangetroffen, is door verscheidene gebeurtenissen van gen 
overdracht aangetoond. De blaCTX-M genen zijn daar misschien wel het meest 
belangrijke voorbeeld van. Deze genen, die hun oorsprong hebben in de 
omgevings-bacterie Kluyvera, zijn momenteel de meest voorkomende oorzaak 
van extended-spectrum β-lactamase (ESBL) productie in Enterobacteriaceae. Er 
zijn meerdere van dit soort uitwisselingen bekend waarbij genetica vanuit 
commensalen of bacteriën uit een water milieu is overgedragen aan menselijke 
pathogenen. Daarnaast wordt van de meeste klinisch relevante ARGs 
verondersteld dat deze afkomstig zijn van niet-pathogene bacteriën.  
Ten gevolge van deze interacties binnen en tussen deze verschillende 
gemeenschappen, moet er rekening worden gehouden met de effecten van 
antibiotica selectiedruk op niet alleen pathogenen, maar ook alle overige 
microben in zulke gemeenschappen, zoals in onze darmen, andere dieren en ook 
de omgeving. Een verhoging van resistoom elementen in deze microbiële 
ecosystemen, zelfs wanneer dit niet direct in menselijke pathogenen is, kan 
uiteindelijk tot in de kliniek reiken en op die manier grote gevolgen hebben voor 
de volksgezondheid. 
 
  
Samenvatting 
 
143 
Het menselijke darmresistoom 
Net zoals elke andere microbiële gemeenschap, bevat het menselijke 
darmmicrobioom talloze ARGs (hoofdstukken 4A, 4B). Met het potentieel van 
horizontale gen overdracht in deze resistentiereservoirs in gedachten, verdient de 
menselijke darmmicrobiota speciale aandacht door de hoge dichtheid aan micro-
organismen. Het gastro-intestinale stelsel wordt constant blootgesteld aan talloze 
bacteriën vanuit de omgeving via bijvoorbeeld voedsel, water, de grond of andere 
mensen en dieren. Deze binnenkomende bacteriën bevatten veelal ARGs, welke 
mogelijk overgedragen kunnen worden aan de oorspronkelijk aanwezige 
bacteriële gemeenschap. Op deze manier kan de voorraad aanwezige 
antibioticaresistentie elementen in de darmmicrobiota verhoogd worden. Hoewel 
enkele studies hebben laten zien dat ARGs al aanwezig zijn op jonge leeftijd en 
zonder voorafgaand antibiotica gebruik, zijn de gegevens over hoe het 
darmresistoom ontwikkelt en wordt beïnvloed door externe factoren nog beperkt. 
Veranderingen in de ontwikkelende microbiota kunnen echter wijzigingen in 
zowel de samenstelling als het daarmee geassocieerde resistoom teweeg 
brengen. 
In hoofdstuk 3 lieten we zien dat al binnen enkele weken na de geboorte 
verschillende ARGs detecteerbaar waren in de darmmicrobiota van kinderen. Op 
latere tijdstippen nam de prevalentie van de meeste genen toe. Hetgeen 
suggereert dat deze genen langzaam accumuleren gedurende de ontwikkeling van 
de microbiota. Het aac(6’)-aph(2”) gen, dat codeert voor aminoglycoside 
resistentie, werd echter minder prevalent over de tijd. Dit duidt erop dat sommige 
ARGs juist verdwijnen of verminderen in aantal. Tijdens de zuigelingenperiode en 
vroege kinderjaren verandert de microbiële samenstelling snel en wordt 
beïnvloed door verschillende factoren. Voorbeelden hiervan zijn de manier van 
geboorte, het type zuigelingenvoeding, de zwangerschapsduur en het antibiotica 
gebruik. Wij hebben laten zien dat de waargenomen veranderingen in ARGs 
gedeeltelijk gecorreleerd waren aan fluctuaties in bepaalde groepen bacteriën 
(bijvoorbeeld een hogere hoeveelheid bacteroides). Hieruit concludeerden we dat 
de samenstelling van het resistoom op deze leeftijd grotendeels gevormd wordt 
door de wijzigingen in de structuur van de bacteriële gemeenschap van de 
darmen. Ook lieten we zien dat factoren zoals de manier van geboorte en de duur 
van het geven van borstvoeding niet alleen invloed had op de darmmicrobiota 
samenstelling, maar ook op de prevalentie van verschillende ARGs. Onze 
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resultaten geven een representatie van de veranderingen in de microbiële 
samenstelling door te kijken naar de verschillende bacteriegroepen. Het uitvoeren 
van 16s rDNA sequencing zou echter een meer gedetailleerde correlatie tussen 
deze veranderingen kunnen verschaffen. In hun studie over de darmresistoom 
ontwikkeling van tweelingen lieten Moore en collega’s zien dat 
omgevingsfactoren in de vroege levensjaren vorm geven aan de resistoom 
ontwikkeling. In overeenkomst met onze resultaten, concludeerden zij dat het 
darmresistoom van de zuigeling waarschijnlijk een weerspiegeling is van de 
bacteriële gemeenschapssamenstelling. Samen met onze resultaten wijst dit erop 
dat vroege blootstelling aan organismen, die resistentiegenen bevatten welke 
gedeeld kunnen worden met opportunistische pathogenen, er toe kan lijden dat 
deze genen gevestigd worden in het resistoom en derhalve een mogelijk risico 
kunnen vormen voor toekomstige infecties.  
 
Reizen en de verspreiding van antibioticaresistentie 
In een tijdperk van toenemende globalisatie is het verkrijgen en de 
verspreiding van antibioticaresistente bacteriën ten gevolge van internationaal 
reizen een grote zorg. De blootstelling aan antibioticaresistente bacteriën tijdens 
een reis vormt een risico voor het ontwikkelen van infecties met zulke resistente 
bacteriën. Daarnaast kan de geografische verplaatsing van resistoom elementen 
ook leiden tot de introductie en verdere verspreiding van deze ARGs in andere 
omgevingen. 
In hoofdstuk 4A hebben we het effect van internationaal reizen op het 
darmresistoom onderzocht in een prospectieve cohort studie. De resultaten van 
deze studie laten zien dat ESBL coderende genen (blaCTX-M) in hoge mate werden 
verworven door reizigers die naar Azië of Afrika waren geweest. Met name 
reizigers die naar het Indiaas subcontinent waren geweest, hadden een hoog 
risico voor de acquisitie van blaCTX-M (>58%). Uit voorgaande studies naar de 
acquisitie van ESBL producerende Enterobacteriaceae door reizigers, bleek ook 
dat dit risico erg hoog was voor bestemmingen in Zuid-Azië (tot wel 88%). Dit 
duidt aan dat reizen naar deze gebieden een belangrijke factor is die bijdraagt aan 
de verspreiding van ARGs van endemische gebieden naar gebieden waar een lage 
prevalentie heerst. Dankzij onze metagenomische aanpak hebben we kunnen 
aantonen dat ook andere ARGs werden verworven tijdens het reizen. Dit werd 
duidelijk door de bevinding dat de plasmide gemedieerde quinolone resistentie 
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genen (qnrB en qnrS) ook in hoge mate verworven werden. Voor qnrS was het 
risico het grootst voor reizigers die naar Azië gingen en vooral voor de reizigers die 
Cambodia, Thailand of Vietnam hadden bezocht (>81% acquisitie). Van het 
laatstgenoemde land werd eerder aangetoond dat het endemisch is voor qnr 
genen. Hoewel onze studie zich richtte op een selectie van ARGs, benadrukken 
deze bevindingen de hoge waarschijnlijkheid dat vele andere ARGs, welke 
endemisch zijn in bepaalde gebieden, door reizigers worden geïntroduceerd in 
gebieden met een lage prevalentie. Zo is er waarschijnlijk ook een import van 
carbapenemase genen vanuit hoge prevalentie landen in de mediterranen zoals 
Italië, Turkije en Griekenland. Reizigers die deze gebieden bezoeken gaan echter 
over het algemeen niet naar reisklinieken waardoor de gegevens hierover helaas 
erg beperkt zijn. Een vervolg onderzoek op deze specifieke studie populatie is niet 
uitgevoerd. Hierdoor is het niet bekend is hoe lang de verworven ARGs in het 
darmmicrobioom aanwezig bleven. Hoewel sommige studies de persistentie van 
verkregen ESBL producerende stammen hebben onderzocht door gebruik te 
maken van kweek gebaseerde methoden, zou het uitvoeren van metagenomische 
studies op dit vlak bijdragen aan het inzicht over de dynamiek en lot van 
verworven ARGs. 
In hoofdstuk 4A beschrijven we de observatie dat sommige ARGs in het 
darmmicrobioom van volwassenen al een hoge prevalentie hadden voorafgaand 
van de internationale reis en dat deze fluctueerden in hoeveelheid. Deze 
fluctuaties konden vermoedelijk worden toegeschreven aan de invloeden van het 
reizen. In hoofdstuk 4B hebben we echter laten zien dat in niet-reizende 
volwassenen, een zelfde soort fluctuatie voor die specifieke ARGs werd 
aangetroffen. Waarschijnlijk vertegenwoordigen deze fluctuaties daarom 
normale, korte termijn veranderingen in de commensale microbiota. 
Veranderingen in de microbiële samenstelling tijdens internationaal reizen is tot 
nu toe nog niet onderzocht, maar zou verband kunnen houden met de acquisitie 
van specifieke ARGs. Het zou bijvoorbeeld zo kunnen zijn dat individuen met een 
verlaagde kolonisatieresistentie vatbaarder zijn voor veranderingen in microbiële 
samenstelling, inclusief een verhoging van het aantal Enterobacteriaceae en de 
daarmee geassocieerde ARGs. 
Hoewel wij en anderen hebben laten zien dat de acquisitie van ARGs en 
antibioticaresistente bacteriën plaats vindt tijdens internationaal reizen, was er 
geen data beschikbaar over hoe snel ARG acquisitie eigenlijk kan plaatsvinden. Dit 
spoorde ons aan om ons te concentreren op de dynamiek van het resistoom 
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tijdens de reis, zoals beschreven in hoofdstuk 5. Door opeenvolgende monsters te 
verzamelen voorafgaand, tijdens en na een reis, hebben we kunnen aantonen dat 
de acquisitie van ARGs al binnen enkele dagen kan plaatsvinden. De mediane tijd 
tot acquisitie was 5 dagen, hetgeen aangeeft dat dit snel plaatsvindt en dat ook 
korte bezoeken aan endemische gebieden voldoende zijn om bij te dragen aan de 
verspreiding van antibioticaresistentie. Ook benadrukt dit de mogelijke implicaties 
voor korte bezoeken aan andere soorten hoog-risico omgevingen zoals 
ziekenhuizen of boerderijen. Terwijl acquisitie binnen zeer korte tijd kan 
plaatsvinden, kunnen de effecten juist langdurig zijn. In onze gelimiteerde 
populatie grootte waren ARGs in sommige gevallen tot 3 maanden na de reis nog 
steeds detecteerbaar. Uit andere studies is gebleken dat resistente organismen, 
welke tijdens het reizen werden verworven, tot 6 maanden tijd persisteerden in 6-
24% van de reizigers. Zo lang het dragerschap van deze resistente bacteriën 
aanhoudt, is er zowel een verhoogd risico voor infecties met zulke bacteriën, als 
het risico voor de verdere verspreiding naar bijvoorbeeld andere leden in een 
huishouden. Bovendien zorgt het voor een constante blootstelling van het milieu 
door de uitscheiding van resistente bacteriën of ARGs (hoodstuk 2). 
Het eerste plasmide gemedieerde colistine resistentie gen (mcr-1) is pas recent 
beschreven. De verspreiding van dit gen kan grote gevolgen hebben omdat multi-
drug resistente bacteriën hierdoor ongevoelig kunnen worden tegen zelfs de 
laatst beschikbare behandelingsoptie. De informatie over de mate van de 
verspreiding van dit gen is nog schaars. Hoewel volgens sommige studies het 
aantal mcr-1 positieve stammen die uit dieren of voedsel zijn geïsoleerd vrij hoog 
was in bepaalde gebieden, zijn rapportages over dragerschap in mensen nog 
sporadisch. In hoofdstuk 6 onderzochten we of reizigers aan dit gen werden 
blootgesteld, en daarmee mogelijk een bijdrage leveren aan de verspreiding 
ervan. In een PCR zijn metagenoom monsters vatbaarder voor het induceren van 
niet-specifieke amplificatie. Dit komt door de hoge diversiteit in het aanwezige 
DNA ten opzichte van bijvoorbeeld DNA dat geïsoleerd is uit bacteriële isolaten. 
Bovendien werd er aangetoond dat de PCR opstelling van Lui et al. vals-positieve 
uitslagen genereerde op bacteriële isolaten. Om op een betrouwbare manier het 
(fecale) metagenoom voor de aanwezigheid van mcr-1 te kunnen onderzoeken, 
hebben we daarom een nieuwe real-time PCR ontworpen. Door gebruik te maken 
van deze gevoelige en specifieke PCR opstelling ondervonden we dat voor 1 
deelnemer het mcr-1 gen in zowel de pre- als post-reis monsters aanwezig was. 
Daarnaast was bij 5 deelnemers enkel het post-reis monster positief bevonden. 
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Dit suggereert dat dit gen al in hoge mate aanwezig is in bepaalde delen van de 
wereld en bevestigd dat het reizen naar zulk hoog-risico gebieden een risico factor 
is voor de acquisitie en verspreiding ervan.  
Bacteriële isolaten die het mcr-1 gen bevatten konden niet van alle fecale 
monsters worden geïsoleerd. Hoewel dit waarschijnlijk komt door de verminderde 
levensvatbaarheid van de bacteriën in deze monsters, zou het interessant zijn om 
de oorsprong van de gedetecteerde genen te achterhalen. Mogelijk zouden deze 
genen namelijk ook aanwezig kunnen zijn in aanvankelijk niet kweekbare 
bacteriën. Zodoende zijn er meer studies nodig die de rol van reizen in het 
verspreiden van mcr-1 uitgebreider bepalen. Door de recente ontdekking van mcr-
1 en de mogelijke implicaties hiervan voor antibiotica therapie, wordt er 
momenteel op verscheidene plaatsen op de wereld een grote hoeveelheid 
onderzoek verricht naar het gen. De resultaten van deze en toekomstige 
onderzoeken zullen leiden tot de benodigde inzichten over de prevalentie en 
belang van het gen in mensen, dieren en de omgeving. Hieruit kan de ernst van de 
mcr-1 situatie worden ingeschat en kunnen er gepaste acties worden 
ondernomen. Een aantal bevindingen wijzen erop dat mcr-1 wellicht een 
oorsprong heeft in bacteriën die geassocieerd zijn met dieren. Hetgeen vraagt 
voor zware restricties of zelfs een verbod op het gebruik van polymyxine in de 
agricultuur. 
 
Concluderende opmerkingen en toekomstperspectieven 
Gezien de opkomst van antibioticaresistentie sinds het gebruik van antibiotica 
door de mens, is het duidelijk dat er inspanningen moeten worden gemaakt om 
de verdere verspreiding hiervan te voorkomen. Wanneer we de therapeutische 
bruikbaarheid wensen te behouden van de huidige en toekomstige antibiotica, 
moeten er bepaalde maatregelen getroffen worden op een globale schaal. Enkele 
van de belangrijke aandachtspunten zijn bijvoorbeeld: (I) de immense 
blootstelling van het milieu aan antibiotica afval; (II) Het grootschalige gebruik van 
antibiotica als groeibevorderaars en profylactische medicijnen in de agricultuur en 
(III) het gebruik zonder voorschrift en inadequaat gebruik van antibiotica voor de 
menselijke geneeskunde. 
Maatregelen om deze aandachtspunten beter te reguleren worden door 
sommige delen van de wereld al genomen. Zo wordt bijvoorbeeld ‘antibiotic 
stewardship’ steeds vaker toegepast in zorginstellingen. Ook worden in 
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verschillende Noord-Europese landen grote vooruitgangen geboekt in het 
verminderde gebruik van antibiotica in de agricultuur. De effecten van zulke 
maatregelen zullen echter voornamelijk gelimiteerd blijven aan specifieke 
gebieden of landen, omdat in andere delen van de wereld extreme 
tegenovergestelden gelden. Zo is de ongereguleerde ‘over de toonbank’ verkoop 
van antibiotica in sommige landen een alledaagse praktijk, is er een gebrek aan 
reguleringen voor antibiotica gebruik in de agricultuur en is de ongecontroleerde 
blootstelling van het milieu aan antibiotica dramatisch. 
Ondanks het feit dat een gebrek aan zulke maatregelen misschien slechts 
regionaal zijn, zal het een wereldwijde toename van antibiotica resistentie blijven 
voortstuwen middels bijvoorbeeld ruilhandel en reisroutes. Er is daarom nog 
steeds een behoefte aan het duidelijker definiëren van de invloed van reizen op 
de verspreiding van antibiotica resistentie. Toekomstige studies moeten tot meer 
verduidelijking leiden betreffende hoelang dragerschap voortduurt na de 
acquisitie van ARGs of resistente bacteriën, welk risico dit vormt en of verdere 
verspreiding plaatsvindt naar bijvoorbeeld andere leden van een huishouden of 
naar het milieu. Daarnaast is de acquisitie van zowel carbapenemase-coderende 
genen als dat van mcr-1 ten gevolge van reizen naar endemische landen nog 
onvoldoende bestudeerd en daarmee een belangrijk aandachtspunt. 
Carbapenems en polymixines zullen steeds vaker benodigd zijn als 
behandelingsoptie. Daarom is het van groots belang om de verspreidingsroutes 
vast te stellen van de genen die coderen voor resistentie tegen deze antibiotica. 
Het ontrafelen van mens-tot-mens of milieu-gerelateerde verspreidingsroutes kan 
leiden tot aangrijpingspunten voor het nemen van extra (hygiëne) 
voorzorgsmaatregelen voor bijvoorbeeld ziekenhuisopnamen van patiënten die 
recent hebben gereisd naar endemische gebieden. Er is ook een behoefte aan het 
in kaart brengen van de gevolgen van de verspreiding van ARGs door menselijke 
handelen in het algemeen. Zo is er bijvoorbeeld weinig kennis over wat de 
gevolgen zijn op het resistoom van een omgeving wanneer er een introductie 
plaatsvindt van ARGs (of de organismen die deze bevatten). Dit heeft betrekking 
op de initiële acquisitie van ARGs in het darmresistoom van mensen of dieren, 
maar ook op de daaruit volgende verspreiding naar bijvoorbeeld de directe 
omgeving, afvalwateren, enzovoorts. Uiteindelijk zal het essentieel zijn om te 
onderzoeken in welke mate zulke effecten verbonden zijn aan de antibiotica 
resistentie zoals die voorkomt in de kliniek. 
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De huidige tegenslag voor laatste redmiddelen van antibiotica tegen multidrug 
resistentie, door de ontdekkingen van mcr-1 en mcr-2, heeft benadrukt dat er een 
dringende nood is aan nieuwe antibiotica. Net zoals de grotendeels onverkende 
bacteriële ecosystemen talloze ARGs bevatten, zijn deze waarschijnlijk ook een 
bron van nieuwe antibiotica. Gelijk aan hoe teixobactin recent is ontdekt, kunnen 
nieuwe manieren om micro-organismen te cultiveren uit ecosystemen zoals grond 
en water omgevingen, de mogelijkheid bieden om nieuwe antibiotica te 
ontdekken. Zoals eerder besproken, zullen strikte regulaties voor het gebruik van 
deze nieuwe antibiotica noodzakelijk zijn. Indien zulke regulaties niet worden 
nageleefd, is er geen reden dat de therapeutische bruikbaarheid niet hetzelfde lot 
zal ondergaan als dat van de huidige antibiotica. Zeer waarschijnlijk zal resistentie 
tegen nieuwe antibiotica voortkomen uit dezelfde ecosystemen als waar deze 
antibiotica ontdekt zijn. Door het toepassen van metagenomics (metagenoom 
technieken) zou deze resistentie kunnen worden ontdekt en gemonitord voordat 
deze opduikt in menselijke pathogenen, als deze daar niet al aanwezig is. Door het 
uitvoeren van functionele metagenomic studies, zullen nieuwe genen die coderen 
voor resistentie tegen de huidige antibiotica worden ontdekt. Dit zal de annotatie 
kracht van sequence gebaseerde studies verbeteren. Hetgeen ervoor zorgt dat er 
meer informatie kan worden gewonnen uit zowel het sequencen van bacteriële 
gemeenschappen als uit al bestaande sequence data. Ook zal het identificeren van 
onbekende ARGs het mogelijk maken om met targeted metagenomic technieken 
zulke  bacteriële gemeenschappen te onderzoeken voor het vóórkomen van deze 
genen. 
Het vóórkomen en de verspreiding van antibiotica resistentie, niet alleen in 
menselijke pathogenen, maar in alle bacteriële ecosystemen die kunnen dienen 
als een potentieel reservoir van resistentie, kan verder worden ontrafeld door 
gebruik te maken van een combinatie van deze verschillende metagenoom 
technieken. Deze inspanningen zullen nodig zijn om de juiste maatregelen te 
kunnen nemen tegen het verspreiden van resistentie tegen zowel de huidige, als 
toekomstige antibiotica. 
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Relevance for society and economy 
The antibiotic resistance encountered in human pathogens is a huge concern 
for public health worldwide. Because of this resistance, effective treatment 
options for bacterial infections are often limited and in some cases may no longer 
be available at all. This reduces clinical efficacy, increases treatment costs and 
causes a great amount of otherwise preventable mortality. In the Review on 
Antimicrobial Resistance, commissioned by the UK government, it was stated that 
“Antimicrobial resistance (AMR) kills around 50,000 people a year in the US and 
Europe, and is estimated to kill more than 700,000 people globally.” [1]. The  
global production and consumption of antibiotics is enormous, and was shown to 
have drastically increased over de last few years [2], causing a constantly 
increasing selection pressure on bacteria in all exposed environments. The use 
and misuse of antibiotics in medicine, agriculture, and aquaculture has been 
linked to the emergence of resistant bacteria in these settings [3-5]. As such, the 
antibiotic resistance problem is rapidly increasing. Moreover, with the lack of 
development of novel antibiotics, the increasing resistance to the current last-
resort antibiotics foreshadows a grim situation where untreatable infections will 
become increasingly more common. 
In order to illustrate how catastrophic the problem is likely to become if the 
current trend is not changed, the authors of the Review on Antimicrobial 
Resistance made crude estimates of the future burdens of antimicrobial 
resistance. They estimated that by the year 2050, 10 million people would die 
annually because of antimicrobial resistance, overtaking even the number of 
deaths attributed to cancer [6]. The economic costs will similarly be enormous, as 
indicated by their estimation that “the world’s GDP will be 2 to 3.5% lower than it 
otherwise would be in 2050”, and that “It would cost the world up to 100 trillion 
USD” [6]. 
 
Target groups 
The antibiotic resistance problem concerns an exceptionally broad audience, 
as anyone can be at risk for unfortunate infections with resistant pathogens. As 
such, this work can be of interest to both professionals in health care as well as 
the general population. In order to achieve appropriate usage of antibiotics, it is 
essential that general practitioners, as well as all medical doctors in health care 
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facilities which prescribe antibiotics understand the mechanisms which drive 
antibiotic resistance. This work may aid in realizing such an understanding. Since 
this work addresses the risks of acquiring antibiotic resistant bacteria as a result of 
international travel, it should also be of interest to general practitioners and 
infection prevention specialists with regards to assessing risk cases for patients. It 
is also important to increase the awareness of the general population on the 
concept of antibiotic resistance, since such an understanding will stimulate the 
responsible use of antibiotic usage. Additionally, this work can be of interest to 
policy makers of government ministries of health, as appropriate government 
regulations  are essential in achieving national and global guidelines to tackle the 
antibiotic resistance problem.   
 
Activities, innovations, planning and realization 
While antibiotic resistance is increasing worldwide, the situation varies 
extensively between different countries. As such, international collaborations are 
required to aid countries which struggle with high and inadequate antibiotic 
usage. Because of the dissemination of antibiotic resistance through trade, travel 
and migration, these problems are a global concern and should be tackled as such. 
Extending the knowledge and resources of countries which are doing relatively 
well in this respect could lead to reduced and better regulated usage of antibiotics 
worldwide. This is essential since the reduction of resistant bacteria in highly 
problematic areas will subsequently result in a decreased spread of antibiotic 
resistance towards other countries.  
An important point of focus would be to work towards a global ban of over-
the-counter sales of antibiotics, along with conservative and appropriate 
prescription by healthcare personal. In order to establish this, it will be necessary  
to create awareness of the consequences of antibiotic use. For healthcare 
professionals, this could be realized by additional trainings. To ensure that 
prescribed antibiotics are used responsibly, awareness must also be created 
among the general population, through e.g. government regulated informative 
commercials or education. Since other animals or even the environment may 
serve as reservoirs of resistance, it is also important to promote regulations of 
antibiotic usage in agriculture. Currently such regulations are non-existent in 
many countries, which attributes to the high rates of resistance encountered in 
animals.  
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Furthermore, by improving the global surveillance of antibiotic resistance in 
both pathogens and commensals, possible sources for the dissemination of 
resistance may be more clearly defined. This work has contributed to identifying 
such sources of dissemination. Moreover, we have provided novel approaches to 
perform antibiotic resistance surveillance in whole microbial communities. As we 
have shown, this allows for the identification of a broader range of risk factors. 
With information obtained from these efforts, the appropriate precautions can be 
undertaken to limit further dissemination of antibiotic resistance. This could be 
reflected in e.g. additional hygiene precautions, controls for imported foods, or 
screening of hospital admittance of patients returning from high risk areas. 
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Dankwoord 
Na al het wetenschappelijke schrijfwerk nu even een moment om terug te 
blikken op de afgelopen vier jaar. Bij de totstandkoming van dit proefschrift zijn 
een hoop mensen betrokken geweest, waarvoor ik ze graag wil bedanken. 
 
Mijn promotieteam 
Mijn copromotores Petra en John, bedankt voor het aanbieden van deze kans, 
voor het vertrouwen, voor de geweldige samenwerking, de constructieve kritiek, 
het dienen als voorbeeld en bovenal voor een geweldige ervaring. Jullie hebben 
mij bij elke stap van het proces begeleid en voorzien van wijsheid. 
Petra, het begon allemaal toen jij me de mogelijkheid bood voor dit 
promotietraject, waarvoor ik ontzettend dankbaar ben. We gingen meteen snel 
van start en hebben altijd een prettige samenwerking gehad. Ook ben ik dankbaar 
voor de vrijheid die jij me in dit project gegeven hebt. Telkens weer wist je me te 
motiveren en de goede richting op te sturen. 
John, ook onze samenwerking verliep vlekkeloos. Bedankt voor het toevoegen 
van jouw enorme kennis en kunde in dit project. Tot slot nog iets wat je vast vaker 
hoort, maar ook ik ga zeggen: ontzettend bedankt voor de hulp bij de statistiek. 
De manier waarop jullie twee samenwerken mag ook zeker even een eervolle 
vermelding krijgen. Of het nu gaat om het aansturen van een project of het 
nakijken van geschreven teksten, jullie zitten altijd op één lijn. Ondanks jullie 
ontzettend drukke agenda’s hebben jullie mij altijd kunnen ondersteunen. Weet 
dat ik jullie beide ontzettend waardeer! 
Mijn promotor, Paul, bedankt voor de gelegenheid om op deze afdeling 
onderzoek te kunnen doen en te kunnen promoveren. Ook uw betrokkenheid bij 
presentaties op congressen en de altijd nuttige feedback op abstracts, artikelen 
en dit proefschrift waardeer ik enorm.  
 
Mijn (ex-) collega’s van de afdeling 
Patrick, het is een tijd geleden sinds wij contact hebben gehad, maar het 
ontbreken van jouw naam hier is absoluut ondenkbaar. Met jou als leermeester 
begon mijn eerste stage bij de MMB Maastricht. Mijn handelingen in het lab 
dragen dan ook tot op de dag van vandaag jouw afdruk. Jij zag het idee om na 
mijn bachelor opleiding nog verder te leren ook helemaal zitten en regelde zelfs 
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een afspraak bij een coördinator van de masteropleiding. Bedankt voor alles, 
mede dankzij jou heb ik zover kunnen komen. 
Ellen, hoewel onze samenwerking grotendeels van vóór mijn promotietijd op 
de afdeling was, wil ik ook u hier voor alles ontzettend bedanken. Regelmatig 
komen wij elkaar nog tegen op congressen en bijeenkomsten, waarbij ik me dan 
telkens een geweldige en leerzame stagetijd bij het MUMC+ herinner. Tot op het 
volgende congres! 
Erik, voor vragen op het lab kon ik bij jou altijd terecht. Inmiddels kennen wij 
elkaar al zo’n 8 jaar en in die tijd heb ik veel van jou kunnen leren. Bedankt voor 
alles, zonder jou zou het C-lab zeker niet hetzelfde zijn. 
Christel en Mayk, wij kennen elkaar al net zo lang en ook jullie wil ik bedanken 
voor alle hulp in het lab. 
Natuurlijk ook aan alle overige mede auteurs van de artikelen: Astrid, 
Christian, Danyta, Jakob, Julius, Lieke, Nathan en Rianne, bedankt voor jullie 
bijdrage en voor de feedback op de publicaties. 
Beste mede (ex-) promovendi, waarvan velen ook (ex-) kamergenoten. Over 4 
jaar tijd zijn er heel wat mensen gekomen en gegaan. Anne, Amita, Birke, Brian, 
Carla, Charlotte, Christel, Danyta, Julius, Kevin, Niels en Tanja; bedankt voor jullie 
hulp, het uitwisselen van gedachten en ideeën, maar ook voor de gezellige 
koffiepauzes, lunches, borrels, uitstapjes en feesten.  
En natuurlijk wil ik alle andere medewerkers van de afdeling bedanken voor de 
samenwerking, voor het delen van jullie kennis en voor de geweldige tijd. 
 
Abdullah, Fahad, Nader and Snehali, since your Dutch has not yet reached 
perfection, I will make it easy on you and write this paragraph in English. Thank 
you all for the times we had together, the interesting stories you shared, and the 
work we did together. 
 
De paranimfen 
Uiteraard ook een aantal woorden voor mijn paranimfen, Dennis en Tim. Al 
sinds de middelbare school zijn we goed bevriend en nu, jaren later, zijn we hier 
beland. Enkele jaren al zijn we nu werkzaam of studerend op steenworp afstand 
van elkaar bij de UM, MAASTRO clinic of het AZM. Het eerste deel van deze 
periode reden we dan ook elke dag met zijn drieën samen naar Maastricht en 
terug. Nadat Dennis naar Maastricht verhuisde, hebben Tim en ik deze traditie 
voortgezet. Samen even goed wakker worden met een ‘bulletje’ (Red Bull), lachen 
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om van alles en nog wat en klagen over de mede weggebruikers: een periode om 
nooit te vergeten! Maar ook jullie zijn bezig met een promotietraject en ik 
verwacht binnenkort dan ook niets dan lovende woorden over mij in jullie 
dankwoorden! 
 
Familie en vrienden 
Mijn hele familie en al mijn vrienden wil ik bedanken voor de betrokkenheid en 
interesse voor mijn werkzaamheden in Maastricht. In de weekenden kon ik 
natuurlijk altijd op jullie rekenen voor de nodige feestjes en ontspanning. 
Elleke, de afgelopen periode heb ik de last van bijna alle huishoudelijke taken 
op jou laten vallen. Ik weet wel dat je dat begrijpt, maar daar gaan we vanaf nu 
weer een eerlijke verdeling in maken. Bedankt voor alle steun en ook voor het 
bijschaven van mijn zwaar verengelste grammatica van de Nederlandse 
samenvatting van dit proefschrift. 
Mam, pap, bedankt voor de kansen en vrijheden die jullie ons gegeven 
hebben. Bedankt voor alle hulp en begeleiding. Dat ik hier ben gekomen heb ik 
aan jullie te danken. 
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